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Mammalian telomeres are nucleoprotein structures consisting of TTAGGG 
tandem repeats bound to a protein complex called shelterin, which protect chromosome 
ends from degradation, fusions and fragility. TRF1, one of the components of the 
shelterin that binds to dsDNA, has been shown to be essential for telomere protection 
and replication. Telomerase is an enzyme composed of a reverse transcriptase (TERT) 
and a RNA template (Terc) that has the ability to add telomere repeats de novo. 
Telomerase is expressed during embryonic development and in adult stem cell 
compartments of several tissues, but its activity is not sufficient to compensate for the 
accumulative telomere erosion associated aging.  
Telomeric repeats can also be found throughout the genome, as Internal or 
Interstitial Telomeric Sequences (ITSs). Furthermore, several shelterins have been 
described to bind to ITSs as well as to other extra-telomeric regions, some of them 
having key roles in transcriptional regulation. Here, we set to address whether TRF1 can 
be found at extra-telomeric sites in cells with both normal and critically short telomeres, 
contributing to the transcriptional alterations associated with aging. In particular, we 
performed a ChIP-sequencing technique to map TRF1 binding sites in wild-type and 
Terc
-/-
 MEFs, concluding that TRF1 is exclusively located at telomeres in this type of 
cells. 
In 2006, Takahashi and Yamanaka achieved the nuclear reprogramming of 
somatic cells by the ectopic addition of the transcription factors Oct3/4, Sox2, Klf4 and 
cMYC, giving rise to the so-called induced pluripotent stem (iPS) cells. IPS cells 
closely resemble ES cells in their global gene expression and epigenetic patterns. 
Besides they overcome the ethical and immune-compatibility issues that limit the 
clinical use of ES cells. Telomerase activity, telomere length and TRF1 levels are 
increased in iPS cells and this increase correlates with higher pluripotency. In this way, 
knowledge of telomere remodeling during reprogramming is crucial for the possible 
applications of iPS cells in regenerative medicine. In this thesis, we demonstrated that 
the shelterin TRF1 is essential for the acquisition and maintenance of pluripotency, 
highlighting the importance of telomere protection and replication in stem cells biology.
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Los telómeros de mamíferos son estructuras nucleoproteicas que consisten en 
repeticiones TTAGGG unidas al complejo proteico shelterin  y que protegen los 
extremos de los cromosomas de la degradación, fusiones y fragilidad. TRF1, uno de 
los componentes del shelterin de unión a DNA de doble hebra, es esencial para la 
protección y replicación telomérica. La telomerasa es una enzima compuesta por una 
transcriptasa reversa (TERT) y un RNA molde (Terc) que tiene la capacidad de 
añadir repeticiones teloméricas de novo a los extremos de los cromosomas. La 
telomerasa se expresa durante el desarrollo embrionario y en los compartimentos de 
células madre adultas en varios tejidos, pero su actividad no es suficiente para 
compensar la erosión telomérica asociada al envejecimiento. 
Las repeticiones teloméricas también se encontran a lo largo del genoma, como 
“sequencias teloméricas intersticiales” o ITSs. Además, se ha descrito que ciertas 
shelterinas se unen tanto ITSs como a otras regiones extra-teloméricas, teniendo 
papeles clave en la regulación transcripcional. En esta tesis, nos propusimos estudiar 
si TRF1 puede unirse a sitios extra-teloméricos en células con telómeros normales y 
críticamente cortos, contribuyendo así a las alteraciones transcripcionales asociadas 
con el envejecimiento. En concreto, realizamos un ChIP-sequencing con el fin de 
mapear los lugares de unión de TRF1 en MEFs wild-type y Terc
-/-
, concluyendo que 
TRF1 está exclusivamente localizada en telómeros en este tipo celular. 
En el 2006 Takahashi y Yamanaka lograron la reprogramación nuclear de 
células somáticas mediante la adición de los factores de transcripción Oct3/4, Sox2, 
Klf4 y c-Myc, dando lugar a las células madre pluripotentes inducidas (iPS). Las 
células iPS son similares a las células madre embrionarias (ES) en su expresión 
génica global y patrones epigenéticos. Adicionalmente, anularían los problemas 
éticos y de inmunocompatibilidad que limitan el uso clínico de las células ES. La 
actividad telomerasa, la longitud telomérica y los niveles de TRF1 aumentan en 
células iPS, estando este aumento correlacionado con la pluripotencia. De este modo, 
un conocimiento de la remodelación telomérica durante la reprogramación es crucial 
para las posibles aplicaciones de las células iPS en medicina regenerativa. En esta 
tesis, hemos demostrado que la proteína TRF1 es esencial para la adquisición y 
mantenimiento de la pluripotencia, enfatizando la importancia de la protección y 
replicación telomérica en la biología de las células madre. 
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3F/ 4F 3/4 reprogramming factors 
4-OHT 4-hydroxytamoxifen 
AB antibody 
ADP adenosine-diphosphate 
  
ALT Alternative Lengthening of Telomeres 
AP Alkaline Phosphatase 
ATM Ataxia Telangiectasia Mutated 
ATR Ataxia Telangiectasia Related 
a.u. Arbitrary units 
BER Base Excision Repair 
BLM Bloom protein 
bp Base pairs 
BSA Bovine serum albumin 
CDK1 Cyclin-dependent kinase 1 
cDNA Complementary DNA 
cm centimeters 
CFS Common Fragile Site 
ChIP Chromatin Immunoprecipitation 
CHK1 Checkpoint kinase 1 
CHK2 Checkpoint kinase 2 
c-MYC myelocytomatosis 
Ctrl Control 
Dapi 4',6-Diamidino-2-phenylindole dihydrochloride 
DC Dyskeratosis Congenita 
DDR DNA Damage Response 
D-loop Displacement loop 
DNA Deoxyrribonucleic acid 
DNA-PK DNA-activated Protein Kinase 
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DKC1 Dyskerin1 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMSO Dimethyl sulfoxide 
dox Doxycycline 
DSBs Double Strand Breaks 
dsDNA Duble-strand DNA 
E Exon 
(e)GFP (Enhanced) Green Fluorescent Protein 
ERT2 Estrogen Receptor T2 variant 
ES(Cs) Embryonic Stem (cells) 
EV Empty Vector 
FACS Fluorescence-activated cell sorting 
FBS Foetal bovine serum 
FDR  False discovery rate 
Fig. Figure 
Fw Forward 
G1/3 First/ Third Generation 
G4 Guanine cuadruplex 
Gapdh Glyceraldehyde-3-phosphate  
GSK3 Glycogen synthase kinase-3 
h hours 
HEK Human Embryonic Kidney 
Helt hTERT immortalized BJ fibroblasts 
HR Homologous Recombination 
hTEP1 Human telomerase-associated protein 1 
I intron 
I4F Inducible four factors 
ICM Inner-cell Mass 
iPS Induced Pluripotent Stem 
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IR Ionizing Radiation 
ITSs Internal/ Interstitial Telomeric sequences 
K5 Keratin 5 (promoter) 
Kb Kilo-bases 
kD Kilo-Daltons 
Klf4 Krüppel-like factor 4 
KO Knockout 
KSR Knockout Serum Replacement 
LIF Leukaemia Inhibitory Factor 
MACS Model-based Analysis of ChIP-seq 
Mbp Megabase-pairs 
MEF Mouse Embryonic Fibroblast 
min minutes 
mRNA Messenger Ribonucleic Acid 
MTS Multitelomeric Signals 
Neo Neomycin selection cassette 
NER Nucleotide Excision Repair 
NHEJ Non-Homologous End Joining 
NLS Nuclear Localisation Signal 
nt nucleotides 
OCT3/4 Octamer3/4 
o/n overnight 
OSK/OSKM Oct3/4, Sox2, Klf4;  Oct3/4, Sox2, Klf4, c-Myc 
P Passage 
PAGE polyacrylamide gel electrophoresis 
PARP1/2 poly-ADP-ribose polymerase 1/2 
PBS Phosphate buffer saline 
PCR  Polymerase chain reaction 
PFA Paraformaldehyde 
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p.i. Post-infection 
PINX1 PIN2-Interacting protein1 
POT1 protection of telomeres 1 
  
Q-FISH Quantitative Fluorescence in situ Hybridization 
qRT-PCR Quantitative Real Time PCR 
RAP1 Repressor Activator Protein 1 
RB Retinoblastoma-Protein 
RT Room Temperature 
RTEL1 regulator of telomere elongation helicase 1 
rtTA Transcriptional activator 
Rv Reverse 
S Subtelomeres 
SAC Spindle Assembly Checkpoint 
SCNT Somatic-cell nuclear transfer 
SDS Sodium dodecyl sulfate 
sec seconds 
S.e.m. Standard error of the mean 
shRNA Short-hairpin RNA 
SMC-1 Structural Maintenance of Chromosomes 1 
SSB Single-strand breaks 
ssDNA Single-strand DNA 
SSEA-1 Stage-Specific Embryonic Antigen 1 
SOX2 Sry-related, HMG box-containing protein 
Sp Super 
TANK1 Tankyrase 1 
TANK2 Tankyrase 2 
Terc Telomerase RNA Component 
TERT Telomerase Reverse Transcriptase 
Tg Transgenic 
TIF Telomere dysfunction Induced Foci 
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TIN2 TRF1 Interacting Protein 2 
T-loop Telomere loop 
TOPOII Topoisomerase II alpha 
TPP1 POT1-TIN2 organizing protein 
TRF1/TERF1 Telomere Repeat binding Factor 1 
TRF2/TERF2 Telomere Repeat binding Factor 2 
TRFH Telomere Repeat binding Factor Homology 
domain 
T-SCE telomeric sister-chromatid exchange 
TSS transcription start sites 
TTF tail-tip fibroblast 
UTR Untranslated region 
WRN  Werner 
WT Wild-type 
XPF Xeroderma Pigmentosum group F 
γH2AX Gamma phosphorylated histone  Histone 2 variant 
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1. Telomere structure 
 “Telomere” is a term that derives from the Greek words telos (end) and meros 
(part). Telomeres are specialized ribonucleoprotein structures at the end of 
eukaryotic chromosomes that protect them from being detected as double-strand 
DNA (dsDNA) breaks (DSBs) by the DNA damage response (DDR) machinery, 
preventing fusions, recombination and degradation (Chan and Blackburn, 2002; de 
Lange, 2005) . In vertebrates, telomeres are composed of heterochomatic tandem 
arrays of TTAGGG repeats bound to a complex of proteins called shelterin or 
telosome, which contributes to the telomere protection and capping (de Lange, 
2005). On average, human telomeres are 10-15 kb long, while in mice telomeres 
span between 25 and 40 kb, depending on the genetic background (Blasco, 2005). At 
the end of the telomere sequences, there is  a single-stranded DNA (ssDNA) 3’ 
overhang of the G-rich strand (G-strand overhang) of approximately 150 to 200 nt, 
which is a direct consequence of the “end-replication problem” (explained later) 
(Fig. 1A). In order to prevent degradation of chromosomal ends by exonucleases or 
processing as DSBs, the G-strand overhang folds back and invades the double-
stranded telomeric region forming the so-called telomere loop (T-loop) and 
generating a displacement loop or D-loop (Griffith et al., 1999) (Fig. 1B). Some 
shelterin components have been shown to influence this T-loop formation (de Lange, 
2005). Because of its G-rich content, G-strand overhangs can form G-cuadruplexes 
(G4 DNA), where each G serves as a donor and acceptor for hydrogen bond 
formation (Fig. 1C). In humans, G-cuadruplexes have been implicated in telomere 
protection and inhibition of telomere elongation by telomerase (Lipps and Rhodes, 
2009). 
Introduction 
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2. The shelterin complex 
 Mammalian shelterin complex is composed of six proteins: telomeric or 
TTAGGG repeat binding factors 1 (TERF1 or TRF1) and 2 (TERF2 or TRF2), 
TRF1-interacting protein 2 (TIN2), protection of telomeres 1 (POT1), the POT1-
TIN2 organizing protein (TPP1, TINT1, PTOP or PIP1) and repressor/activator 
protein 1 (RAP1) (de Lange, 2005) (Fig. 2A). From these six proteins only three of 
them bind directly to DNA: TRF1 and TRF2 to dsDNA and POT1 to the single- 
stranded 3’ overhang. TRF1 and TRF2 bind independently to the 5'-YTAGGGTTR-
3' sequence, forming homodimers or oligomers (Broccoli et al., 1997; Court et al., 
2005). POT1 also has strong sequence specifity binding single-stranded 5’-
TAGGGTTAG-3’ sites at the G-strand overhang and the displaced G-strand at the D-
loop (Baumann and Cech, 2001; Lei et al., 2004; Loayza et al., 2004) (Fig. 2B). 
POT1 interacts with TRF1 and this interaction is proposed to affect the loading of 
POT1 on the ssDNA (Loayza and De Lange, 2003). While humans contain only one 
POT1 gene, mouse Pot1 has two paralogs, Pot1a and Pot1b, which carry out 
different functions (Hockemeyer et al., 2006). POT1 is recruited to telomeres by its 
binding to TPP1 (Liu et al., 2004), which is also able to bind to TIN2 protein (Ye et 
al., 2004b). TIN2 binds to TRF1 and TRF2 via different domains and is necessary for 
Figure 1: The structure of 
mammalian telomeres. (A) 
Mammalian chromosomes 
end in an array of TTAGGG 
repeats. The telomere 
terminus contains a single-
stranded G-rich 3’-overhang 
of 150-200 nt. (B) Scheme 
of the T-loop structure 
showing the invasion of the 
dsDNA by the G-overhang, 
leading to the formation of 
the D-loop. (C) Structure of 
the G-cuadruplex (G4) DNA 
(Adapted from  Nandakumar 
and Cech, 2013). 
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the stabilization of these proteins at telomeres. Besides, it recruits the TPP1-POT1 
complex to the rest of the shelterins, acting as a bridge that links the double-stranded 
and single-stranded binding proteins of the shelterin complex (Chen et al., 2008; Kim 
et al., 2004; Ye et al., 2004a). Lastly, RAP1 is recruited to telomeres by its binding to 
TRF2 (Celli and de Lange, 2005; Li and de Lange, 2003).  
 
 
 
 
 
 
  
 
 
 
 
 
Complete abrogation of each of these proteins leads to early embryonic 
lethality in mice, with the exception of RAP1 and POT1B. Shelterins have 
fundamental roles in telomere biology, associated with T-loop formation (TRF2 and 
TRF1), protection and recombination (TRF2, TRF1, TIN2, TPP1 and RAP1), 
inhibition of DDR (TRF2, TRF1, TPP1, POT1, RAP1), G-strand overhang protection 
(POT1), telomerase recruitment (TPP1), telomere length regulation (TRF2, TRF1, 
TIN2, TPP1 and RAP1) or telomere replication (TRF1) (Martinez and Blasco, 2011). 
In addition to the core proteins that form the shelterin complex, accessory 
factors are transiently associated with telomeres. Some examples are the TRF1-
interacting ankyrin-related poly-ADP-ribose polymerase (PARP) Tankyrase 1 
(TNK1) and 2 (TNK2), which regulate TRF1 binding to telomeres (Cook et al., 
2002; Smith et al., 1998), PIN2/TERF1 interacting protein (PINX1), which directly 
Figure 2: Shelterin complex and 
T-loop structure. (A) Schematic 
depiction of the nucleoprotein 
structure of a telomere and the 
binding pattern and partners of the 
shelterin proteins. Of note is that 
only TRF1, TRF2 and POT1 are 
directly binding to telomeric DNA. 
RAP1, TIN2 and TPP1 are localized 
at the telomere via a linker protein. 
(B) Telomere nucleoprotein 
structure forming the T-loop and 
binding of the corresponding 
shelterins (Adapted from Martinez 
and Blasco, 2011).  
A 
B 
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binds and inhibits telomerase (Soohoo et al., 2011), MRE11/ NBS1/ RAD50 
complex, involved in the detection of DSBs  and repair by homologous 
recombination (HR) (Zhu et al., 2000), XPF/ERCC1 endonucleases complex, a 
component of the nucleotide-excision repair (NER) pathway (Zhu et al., 2003), the 
DNA-PKs complex, which are kinases implicated in non-homologous end joining 
(NHEJ) (d'Adda di Fagagna et al., 2001; Yang et al., 1999),  the RecQ helicases 
WRN and BLM, associated with unwinding DNA during the replication process 
(Opresko et al., 2002), the ADP-ribosylases 1 (PARP1) and 2 (PARP2), implicated 
in base excision repair (BER) (Dantzer et al., 2004) and Apollo, a 5’-exonuclease 
involved in telomere end modulation) (Wu et al., 2012). The majority of these factors 
are recruited to telomeres through their interaction with the shelterin components, 
mostly TRF1 and TRF2 (Chen et al., 2008), having essential roles in the 
maintenance, protection and function of telomeres. 
 
3. Telomere protection and DDR 
Mammalian cells respond to the presence of DNA lesions by activating a DDR 
that consists in signaling cascades including the detection, degradation or repair of 
the fragments, cell cycle arrest and/or death. DNA breaks can activate two signaling 
pathways: ataxia telangiectasia mutated (ATM) kinase pathway, primarily activated 
by DSBs, and ATM-RAD3-related (ATR) kinase pathway, activated by ssDNA 
breaks (SSBs). Once any of these two kinases are activated, they phosphorylate the 
histone variant H2AX on Serine 139 (H2AX), inducing the accumulation of 
detectable DNA damage foci. ATM and/or ATR activation induces the checkpoint 
proteins CHK1 and CHK2 and ultimately leads to the activation of the tumor 
suppressors p53 and p21, triggering cell cycle arrest, senescence and/or apoptosis. In 
parallel, recognition of DSBs also drives the repair of these DNA fragments by two 
different pathways, HR and NHEJ (Denchi, 2009). 
Telomeres are potential sites of genome instability, hence its maintenance and 
protection requires the inhibition of DDR signals. Some of the shelterins contribute 
to this inhibition and, hence to the protection of telomeres. Abnormal or impaired 
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telomeres that are critically short or unprotected due to shelterin deficiencies are 
recognized as DSBs by the DDR machinery, triggering the accumulation of DNA 
damage foci known as telomeric-induced damage foci (TIF) and chromosomal 
aberrations (de Lange, 2009; Denchi, 2009; Martinez et al., 2009; Tejera et al., 
2010), ultimately resulting in cell cycle arrest, senescence and/or apoptosis. The non 
proper inhibition of NHEJ pathway can lead to chromosome or sister chromatid end-
to-end fusions, while the activation of HR would lead to recombination between 
telomeres (telomeric sister-chromatid exchanges, T-SCE) or telomeres and other 
sequences in the genome. Chromosome end-to-end fusions are tremendously 
deleterious for the cell because they give rise to dicentric chromosomes that are 
unstable during mitosis, promoting genome instability and eventually, cancer. 
 
4. Telomere shortening and replicative senescence 
 During the DNA replication that takes place every cell division, telomeres 
shorten around 50 to 200 bp as a result of the “end-replication problem”. This “end-
replication problem” resides in the notion that conventional DNA polymerases need 
a primer to initiate the synthesis and can only add bases to the 3’ end, causing the 
discontinuous and incomplete replication of the lagging strand (3’ 5’) of linear 
chromosomes (Ohki et al., 2001; Okazaki et al., 1967). It has been postulated that 
additional telomere loss occurs due to post-replicative processing of the C-rich 
strand, giving rise to the 3’ G-overhangs (Makarov et al., 1997).  
 “Replicative senescence” is a phenomenon that was first described by Hayflick 
in the sixties and is based on the idea that most cell types have a limited proliferative 
capacity, becoming senescent after a number of divisions (Hayflick, 1965). These 
senescent cells are metabolically active but unable to proliferate. It is very well 
established that telomere shortening is the major mechanism that induces replicative 
senescence (Bodnar et al., 1998). Progressive erosion of telomeres is propagated into 
daughter cells and as a consequence of this telomere loss, less shelterin complex can 
be recruited to the end of the chromosomes. This would eventually results in 
critically short or uncapped telomeres, which would ultimately lead to cell cycle 
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arrest, apoptosis or senescence (d'Adda di Fagagna et al., 2003). This cell cycle arrest 
in response to telomere dysfunction differs from humans to mice. While in humans it 
is mediated by p53 and RB pathways, in mice the activation of p53 suffices to induce 
cell cycle arrest (Smogorzewska et al., 2000).  
 
5. Telomere elongation 
5.1. Telomerase  
In 1985, Greider and Blackburn demonstrated the existence of an enzymatic 
activity that added telomere sequences to the 3’ ends of chromosomes, the so-called 
telomerase (Greider and Blackburn, 1985).  Telomerase, the main regulator of 
telomere length in mammalian cells (Chan and Blackburn, 2002), is able to re-
elongate telomeres de novo, compensating for the telomere loss associated with cell 
division (Blackburn, 2001; Collins and Mitchell, 2002). This enzyme is a 
ribonucleoprotein complex that consists of two molecules each of a telomerase 
reverse transcriptase component (encoded by Tert gene) and a telomerase RNA 
component (encoded by the Terc gene), which serves as a template for telomere 
elongation. In addition, a single molecule of dyskerin 1 (DKC1) is retained in the 
core telomerase complex, binding and stabilizing Terc (Blasco, 2007) (Fig. 3). 
 
 
 
In humans, telomerase activity is restricted to embryonic development, 
embryonic stem (ES) cells, germ cells, adult stem cell compartments, certain types of 
Figure 3: Telomerase 
structure and telomere 
elongation. The telomerase 
enzyme consists of two 
molecules of TERT and Terc 
subunits and a molecule of 
DKC1. Telomerase recognizes 
the 3’ end of the G-rich 
telomere strand and adds 
telomeric repeats de novo 
(Blasco, 2007). 
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somatic cells (e.g. lymphocytes) and most cancer cells (85-90%), allowing them to 
maintain telomere length and escape cellular crisis (Allsopp et al., 2003; de Lange 
and DePinho, 1999; Greenberg et al., 1998; Hiyama and Hiyama, 2002; Hoffmeyer 
et al., 2012; Montgomery et al., 2011; Schepers et al., 2011). In contrast, telomerase 
is active at low levels in a large repertoire of somatic mouse cells (Forsyth et al., 
2002; Greenberg et al., 1998). Although Terc expression can also be regulated, a 
major determinant of telomerase activity is the transcriptional regulation of the 
catalytic subunit Tert. Tert transcription is influenced by several factors associated 
with cell cycle, TGF-, PI3K/AKT or NF-B pathways (Cifuentes-Rojas and 
Shippen, 2012; Daniel et al., 2012). Some examples are SP1, WT1 or the oncogenic 
transcription factors c-MYC (Greenberg et al., 1999), NF-B (Yin et al., 2000) and 
-catenin (Zhang et al., 2012). Nevertheless, TERT can also be modulated by post-
translational modifications like phosphorylation or ubiquitylation. Besides, 
telomerase activity can be regulated by interaction with other proteins. For instance, 
the C-terminus of p53 interacts with the N-terminus of human telomerase-associated 
protein 1 (hTEP1) and inhibits telomerase activity in vitro (Li et al., 1999). Finally, 
some shelterins affect the recruitment of telomerase to telomeres. Specifically, TPP1 
contains a telomerase-interacting N-terminal domain and it has been involved in the 
recruitment of telomerase to chromosome ends (Tejera et al., 2010; Xin et al., 2007). 
In contrast, TRF1 and TRF2 are thought to be negative regulators of telomere length 
by hampering the access of telomerase to telomeres (Smogorzewska et al., 2000). 
It is well established that telomerase has non-canonical functions unrelated to 
telomere lengthening, some of them dependent on its catalytic activity. It has been 
demonstrated that TERT can regulate cell growth and proliferation, independent of 
its role on telomeres. It is also involved in the transcriptional or post-transcriptional 
regulation of NF-B, -catenin, VEGF or TGF- pathways, which are master 
regulators of many oncogenic pathways (Low and Tergaonkar, 2013). In fact, Tert 
overexpression increments the proliferative potential of Mouse Embryonic 
Fibroblasts (MEFs) by targeting TGF- pathway in a telomere-length independent 
manner, even if it requires the formation of TERT/Terc complexes (Geserick et al., 
2006). Moreover, it has been reported that telomerase contains mitochondria 
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targeting signals and that exogenously expressed telomerase can localize to the 
mitochondria, regulating apoptotic responses to oxidative stress (Kovalenko et al., 
2010; Santos et al., 2004; Santos et al., 2006). 
 
5.2. Alternative Telomere Lengthening (ALT) 
  In the absence of functional telomerase, some immortal cell lines and tumors 
(Henson et al., 2002), cells from the early embryo cleavage stage (Liu et al., 2007) 
and even some normal mouse somatic cells (Neumann et al., 2013) present other 
strategies to maintain telomere length, such as Alternative Telomere Lengthening 
(ALT). ALT mechanism involves HR between telomeres and subtelomeres (S), the 
chromosomal regions immediately adjacent to telomeres that expand around 3 Mbp 
from telomeres and also contain repetitive stretches of DNA. Cells that use this 
pathway are characterized by highly heterogeneous telomere lengths, with the 
simultaneous presence of long and short telomeres in the same nucleus (Dunham et 
al., 2000).  
 
6. Telomeres in aging and cancer 
Progressive telomere attrition is observed during normal aging both in humans 
and mice (Collins and Mitchell, 2002), being one of the hallmarks of this process 
(Blasco, 2005; Lopez-Otin et al., 2013). As we mentioned before, telomerase is 
active in adult stem cell compartments, which contain the cells with the longest 
telomeres in an organ and efficiently repair lesions and repopulate tissues in young or 
adult organisms. In contrast, in old organisms progressive telomere shortening 
compromises the ability of adult stem cells to repair tissues, preventing the 
mobilization of stem cells from their niches and leading to tissue degeneration 
(Flores et al., 2008). A number of age-related pathologies and premature aging 
syndromes, such as Werner and Bloom syndromes or ataxia telangiectasia, are 
characterized by a faster-than-normal rate of telomere shortening, reinforcing the 
idea that telomere loss is a cause of organism aging. Furthermore, mutations in the 
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different components of telomerase as well as in some of the shelterins (e.g. TIN2) 
have been linked to rare human genetic degenerative diseases (Armanios and 
Blackburn, 2012). These telomere syndromes are associated with the presence of 
short or dysfunctional telomeres, exhibiting a characteristic failure in the 
regenerative capacity of tissues (Donate and Blasco, 2011). For instance, mutations 
in any of the components of telomerase (Tert, Terc or Dkc1) can lead to a severe 
form of bone marrow deficiency known as dyskeratosis congenita (DC). DC is 
characterized by mucosal leukoplakia, nail dystrophy and abnormal skin 
pigmentation (Dokal, 2000). Other examples of telomere syndromes are aplastic 
anaemia and idiopathic pulmonary fibrosis (Armanios et al., 2007; Tsakiri et al., 
2007). 
Cancer and aging share common origins and both are intimately associated 
with the accumulation of DNA damage. Tumor cells with insufficient telomerase 
activity that divide without control would undergo telomere erosion that could have a 
dual role in cancer progression. On the one hand, dysfunctional telomeres can trigger 
a DDR and act as a tumor suppressor inducing apoptosis and/or senescence. On the 
other hand, in the absence of a functional DDR, dysfunctional telomeres would give 
rise to genome instability, favoring transformation and tumor development (Artandi 
et al., 2000; McClintock, 1941). In both human and mouse cancer cells Tert is 
transcriptionally activated to maintain telomere length and to enable “replicative 
immortality”, which is one of the hallmarks of cancer (Hanahan and Weinberg, 2000, 
2011). Besides, non-canonical functions of telomerase have also been associated 
with promotion of the rest of the hallmarks of cancer, underlining the determinant 
role of telomerase in cancer (Low and Tergaonkar, 2013). 
 
6.1. Telomerase mouse models 
The generation of telomerase-deficient mice (Terc
-/-
 mice) was decisive to 
demonstrate the importance of telomerase in the maintenance of telomeres in vivo, 
both in cancer and aging. In contrast to knockout mice for most of the shelterins, 
telomerase deficient mice (Terc and Tert KO mouse models) survive to adulthood.   
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Terc
-/- 
mice exhibit an accelerated telomere shortening, leading to the loss of 
telomere protection and end-to-end fusions (Blasco et al., 1995; Blasco et al., 1997; 
Herrera et al., 1999a; Lee et al., 1998). Successive generations of Terc
-/-
 mice (G1 to 
G3) display a progressive telomere shortening linked to a progressive decrease in 
both median and maximum longevity (Herrera et al., 1999b). Similar phenotypes 
were described in Tert knockout mice (Sahin et al., 2011). Transgenic mice 
overexpressing Tert in stratified epithelia (K5-Tert) show a decreased lifespan 
compared to wild-type cohorts associated with a higher incidence of preneoplastic 
and neoplastic lesions in various tissue types (Gonzalez-Suarez et al., 2002). 
Additionally, they are more susceptible than wild-type mice to develop tumors when 
subjected to chemical carcinogenesis of the skin (Gonzalez-Suarez et al., 2001). 
However, when Tert is overexpressed in a context of cancer-resistant mice, by 
combination with overexpression of the tumor suppressors p53, p16 and p19ARF 
(Sp53/ Sp16/ SpArf/TgTert), mice show a retardation in the onset of degenerative 
lesions, attenuation of the symptoms of aging and a significant extension of median 
and maximum lifespan. Furthermore, they have longer telomeres than wild-type mice 
with less DNA damage (Tomas-Loba et al., 2008). Recently, two studies in mice 
demonstrated that Tert overexpression is able to delay aging without increasing 
cancer incidence (Bernardes de Jesus et al., 2012; Jaskelioff et al., 2011). 
 
7. Telomere repeat binding factor 1 (TRF1) 
TRF1, the first mammalian telomeric protein identified, binds to dsDNA as a 
homodimer or oligomer (Zhong et al., 1992). Murine TRF1 is a 56 kD and 421 
aminoacids protein that contains four functional domains: the amino-terminal N-
domain, the TRF homology (TRFH) domain, which facilitates the homodimerization 
and interaction with TIN2 protein, the nuclear localization signal (NLS) domain and 
the highly conserved cSANT/MYB DNA binding domain (Bianchi et al., 1997; 
Broccoli et al., 1997; Fairall et al., 2001; Poulet et al., 2012; Smith and de Lange, 
1997) (Fig. 4). The structure of TRF1 protein only differs from that of TRF2 in the 
N-terminal domain, which is acidic in TRF1 and basic in TRF2. 
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TRF1 protein is implicated in several functions as T-loop formation and 
telomere capping, telomere replication, telomere protection from DDR, telomere 
length maintenance, resolution of sister telomeres or mitosis. Cell-based in vitro 
studies in humans using overexpression of TRF1 or dominant-negative TRF1 mutant 
alleles suggested a role for TRF1 as a negative regulator of telomere length, by 
inhibition of telomerase access to telomeres (Ancelin et al., 2002; Smogorzewska et 
al., 2000; van Steensel and de Lange, 1997). Equally, Trf1 overexpression in the 
context of mouse epidermis (K5-Trf1 mice) was reported to lead to telomere 
shortening in vivo, by augmenting XPF nucleolytic activity at chromosome ends 
(Munoz et al., 2009). A similar but more severe phenotype was also described for 
targeted Trf2 overexpression to mouse epithelia (Munoz et al., 2005). Complete Trf1 
deletion in mouse leads to early embryonic lethality, at day 5 to 6 post-coitus, 
without any defects in telomere length or capping (Karlseder et al., 2003). 
Conditional Trf1 knockout mouse models showed a critical role of TRF1 in telomere 
capping, protection and replication, preventing telomere fusions and fragility 
(Martinez et al., 2009; Sfeir et al., 2009). Subsequently, Trf1 deleted MEFs show 
chromosomal aberrations and massive TIF induction, triggering a p53 and RB 
mediated senescence. Trf1 deletion in stratified epithelia (Trf1
/
 K5-Cre mice) 
causes perinatal death in mice and severe skin degeneration effects such as 
hyperpigmentation, lack of mature hair follicles and missing sebaceous glands.  P53 
deletion in these mice rescues mouse survival, indicating that the observed 
Figure 4: TRF1 protein structure. TRF1 binds to dsDNA as a dimer or oligomer through 
its C-terminal MYB domain. The binding sequence of each MYB domain consists in the 
half-site 5’-YTAGGGTTR-3’. Dimerization is mediated by the TRFH domains. The N-
terminal acidic domain is indicated (D/E) (Adapted from Diotti and Loayza, 2011). 
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phenotype is p53 mediated (Martinez et al., 2009). TRF1 has also been reported to be 
necessary for the efficient replication of telomeres, preventing fork stalling (Sfeir et 
al., 2009). Telomeres challenge the DNA replication machinery due to their 
repetitive sequences and enrichment in G-cuadruplexes. In fact, they can resemble 
common fragile sites (CFS), which are chromosomal loci known to be hotspots for 
DNA breakage under conditions that induce replication stress and prone to 
replication fork stalling (Sutherland et al., 1998). It has been suggested that TRF1 
facilitates telomere replication by recruitment of BLM and RTEL1, two helicases 
that have been implicated in the removal of G-cuadruplexes (Sfeir et al., 2009). 
Likewise, topoisomerase II (TOPOII), an enzyme essential for resolution of DNA 
replication intermediates, was recently shown to bind to telomeres in a TRF1-
dependent manner (d'Alcontres et al., 2014). 
On top of that, TRF1 has been reported to carry out additional functions in 
mitosis. Overexpressed TRF1 in K5-Trf1 mice was also shown to co-localize with 
the spindle assembly checkpoint (SAC) proteins BUBR1 and MAD2 and to result in 
aberrant mitosis (Munoz et al., 2009). In fact,  TRF1 is necessary for the telomeric 
localization of these SAC proteins In mitosis, sister telomeres associate and the 
resolution of this association is required for progression through mitosis (Dynek and 
Smith, 2004). In this sense, TRF1 has been described to mediate telomere 
associations, since Trf1 overexpression prevents proper resolution of telomeres 
during mitosis. Cyclin b-dependent kinase 1 (CDK1), a key mediator of mitotic 
entry, regulates TRF1 to modulate the resolution of telomeres. CDK1 phosphorylates 
TRF1 at T371, keeping TRF1 free of telomere chromatin and protected from 
proteasome-induced protein degradation. This phosphorylation is upregulated during 
mitosis and it facilitates temporal telomere deprotection, essential for sister telomere 
resolution (McKerlie and Zhu, 2011). Lastly, Trf1 overexpression is also connected 
with increased telomere recombination in K5-Trf1 mice and in ES cells (Lisaingo et 
al., 2014; Munoz et al., 2009). 
The abundance of TRF1 as well as its binding to DNA and other proteins for 
the execution of its multiple roles is subjected to a complex post-translational 
regulation, which is cell-cycle dependent. For instance, TNK1 and TNK2 bind to 
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TRF1 N-terminus and negatively regulate TRF1 binding to telomeres by ADP-
ribosylation (Cook et al., 2002; Donigian and de Lange, 2007; Smith et al., 1998). 
This post-translational modification of TRF1 leads to its release from telomeres, 
promoting ubiquitylation and consequent degradation of this protein. As it is 
explained above, CDK1 can phosphorylate TRF1 protecting it from degradation. 
PINX1 is also able to interact with and stabilize TRF1(Yoo et al., 2014) . 
Furthermore, TRF1 has been reported to be phosphorylated by other several kinases 
including AKT, ATM, Aurora A, CK2 and PLK1 (Walker and Zhu, 2012). 
 
8. Interstitial Telomeric Sequences (ITSs) 
In addition to their location at telomeres, TTAGGG repeats can be found at 
internal chromosomal sites, the so-called Internal or Interstitial Telomeric Sequences 
(ITSs) (Meyne et al., 1990). Alike telomeres, ITSs also resemble fragile sites. Two 
classes of ITSs exist in mammals: long blocks of mainly pericentromeric, 
heterochromatic ITSs (het-ITSs), present only in some species, such as the Chinese 
Hamster, and short ITSs, present at internal positions of ostensibly all vertebrate 
genomes. Some of these short ITSs are part of subtelomeric regions. In humans and 
mice, 83 and 244 non-subtelomeric short ITSs have been characterized, respectively. 
However, no het-ITSs have been detected in these two species. ITSs in rodents are 
longer than in primates, what is probably connected with their longer telomeres 
(Nergadze et al., 2007; Ruiz-Herrera et al., 2008). The origin of ITSs seems to be 
related with chromosome fusions or telomeric hexamers insertions in the genomes 
during the repair of DSBs (Messier et al., 1996). However, their biological role still 
remains unknown.  
 
 
9.  Extra-telomeric binding of shelterins 
Aside from their fundamental role in telomere biology, recent evidence 
suggests additional functions of some of the shelterins by binding to extra-telomeric 
DNA regions. In particular, the ortholog of mammalian RAP1 in budding yeast, 
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scRap1, binds to not only telomeric but also extra-telomeric DNA, acting as a 
transcription factor (Buchman et al., 1988; Capieaux et al., 1989) and this is 
conserved in mammals. It was recently reported that mouse RAP1 is able to bind to 
inter-genic and intra-genic extra-telomeric sites, some of them ITSs. RAP1 shows 
enrichment at S regions, where its binding induces gene silencing. Akin to what 
happens at telomeres, TRF2 mediates binding of RAP1 to DNA in ITS regions 
(Martinez et al., 2010). Similarly, a recent study in humans described that TRF2 and 
RAP1 proteins occupy a limited number of interstitial regions throughout the genome 
and also regulate gene expression (Yang et al., 2011). Taz1, the fission yeast 
ortholog of mammalian TRF1 and TRF2, involved in telomere protection and 
recruitment of Rap1 to telomeres (Cooper et al., 1997; Kanoh and Ishikawa, 2001), 
binds ITSs and plays an essential role in the “replication timing control” (Tazumi et 
al., 2012). In agreement with this, a recent study reported restricted abilities of TRF1 
and TRF2 proteins in binding extra-telomeric sites of the genome in human tumor 
cell lines, most of them ITSs (Simonet et al., 2011). In addition, TRF1 and other 
shelterins can bind to an ITS present at human chromosome 2q14 that forms a CFS, 
stabilizing it (Bosco and de Lange, 2012). Furthermore, in Chinese hamster cells, 
which contain long blocks of het-ITSs representing about 5% of their genome (Day 
et al., 1998). TRF1 is involved in protection of these internal (TTAGGG)n repeats 
from breaks and chromosome rearrangements (Krutilina et al., 2001; Krutilina et al., 
2003). 
 
 
10. Nuclear reprogramming 
ES cells (ESCs) are pluripotent stem cells that have self-renewal capability and 
can differentiate into all of the three germ layers of the embryo (ectoderm, mesoderm 
and endoderm).  ES cells were first isolated from the mouse inner cell mass (ICM) of 
blastocysts in 1981 (Evans and Kaufman, 1981; Martin, 1981) . During development, 
cells gradually lose their self-renewal and differentiation capacities. Remarkably, 
differentiated cells can be reverted to a more pluripotent state by nuclear 
reprogramming, which involves genome-wide changes in chromatin structure and 
gene expression (Gurdon and Melton, 2008; Hochedlinger and Plath, 2009; Rideout 
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et al., 2001; Yang and Smith, 2007). Nuclear reprogramming can be achieved by 
three different approaches. The first one is somatic cell nuclear transfer (SCNT), 
which is based on the insertion of the nucleus of a differentiated somatic cell into an 
enucleated, unfertilized oocyte of the same species (Wilmut et al., 1997). Another 
strategy is the fusion of differentiated cells with ES cells (Tada et al., 2001). The 
most recent approach was described in 2006 by Takahashi and Yamanaka, consisting 
in the direct reprogramming to a state of pluripotency through the ectopic expression 
of defined transcription factors which give rise to the so-called induced pluripotent 
stem (iPS cells or iPSCs) (Takahashi and Yamanaka, 2006). 
 
 
11. Induced Pluripotent Stem (iPS) Cells 
The achievement of iPS cells was a breakthrough in the field of regenerative 
medicine, as they represent a new source of patient-specific stem cells with great 
potential for the study and treatment of human diseases. These cells overcome the 
ethical and technical problems associated with the use of human embryos, as well as 
the potential rejection by the immune system. 
Like ES cells, iPS cells have the properties of self-renewal and differentiation 
into all three germ layers. They can also contribute to chimeric mice, go to germ line 
transmission (Takahashi and Yamanaka, 2006) and directly develop into mice by 
tetraploid complementation assay (Kang et al., 2009; Zhao et al., 2009). Mouse and 
human iPS cells possess morphological, growth, molecular and developmental 
features that closely resemble those of ES cells, including similar global gene 
expression and epigenetic patterns (Amabile and Meissner, 2009; Huang et al., 
2014). IPS cells are also similar to ES cells in their shortened cell cycle compared to 
somatic cells. They show a shorter G1 phase with the loss of G1/S checkpoint, 
promoting rapid progression through successive rounds of replication (Becker et al., 
2006; Momcilovic et al., 2010). Because of the major risk of suffering replication 
errors, both iPS and ES cells have more stringent mechanisms to protect genome 
stability like G2/M cell cycle arrest, hypersensitivity to DNA damage, efficient DSBs 
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repair mechanisms and highly proficient antioxidant defense (Giachino et al., 2013; 
Huang et al., 2014; Momcilovic et al., 2010). 
The two main limitations for the clinical use of this technology reside in the 
inefficient and stochastic characteristics of the reprogramming process and the 
oncogenic potential of the viral integration in the host genome. Since the original 
publication, much effort has been made in the field of reprogramming trying to 
unveil the mechanisms of this process and to ameliorate the technique, so as to bring 
iPS cells closer to clinical applications. The initial cocktail used to obtain iPS cells 
from mouse and human fibroblasts comprised the following transcription factors, 
typical of ES cells:  Oct3/4 (Pou5f1, Octamer3/4), Sox2 (SRY box-containing gene 
2), Klf4 (Krüppel-like factor 4) and c-Myc (myelocytomatosis oncogene) (Takahashi 
et al., 2007; Takahashi and Yamanaka, 2006). Other researchers utilized different 
cocktails including the cellular factors Oct3/4, Sox2, Nanog and Lin28, achieving a 
similar outcome (Yu et al., 2007). Some of the relevant advances of the last years in 
the iPS field are the removal of the oncogenic factor c-Myc from the reprogramming 
cocktail, reported to be dispensable for the reprogramming of both mouse and human 
fibroblasts (Nakagawa et al., 2008; Wernig et al., 2008), the obtaining of integration-
free iPS cells (Anokye-Danso et al., 2012; Kaji et al., 2009; Miyoshi et al., 2011; 
Okita et al., 2011; Okita et al., 2008; Stadtfeld et al., 2008b; Wang et al., 2011; 
Woltjen et al., 2009; Yu et al., 2009), the characterization of p53, p21 and 
INK4/ARF tumor suppressors as a barrier for reprogramming (Hong et al., 2009; 
Kawamura et al., 2009; Li et al., 2009; Marion et al., 2009a; Utikal et al., 2009), the 
chemical reprogramming using small-molecules (Hou et al., 2013; Li et al., 2012; Li 
et al., 2011; Zhu et al., 2011) and the achievement of in vivo reprogramming in mice 
(Abad et al., 2013). Regarding the dynamics of the reprogramming process, it is 
known that while downregulation of Thy1 and subsequent upregulation of SSEA-1 
occur at early time points, reactivation of endogenous Oct3/4, Sox2, Nanog and Tert 
and the silent X chromosome mark late events in the reprogramming process 
(Stadtfeld et al., 2008a) (Fig. 5). 
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11.1. iPS cells and telomeres 
The successful use of iPS cells in regenerative medicine requires unlimited 
proliferative potential of these cells, genomic integrity and differentiation capacity of 
these cells. In this regard, maintenance of telomere length and function is critical. 
One of the main characteristics of iPS cells is their high telomerase activity, similar 
to that of ES cells (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). 
Reprogramming factors have been associated with the regulation of telomerase 
components transcription, inferring that they could be directly implicated in the 
activation of telomerase during reprogramming. C-MYC transcriptionally 
upregulates Tert expression (Drissi et al., 2001; Flores et al., 2006; Wu et al., 1999), 
but its ectopic expression is not necessary for efficient reprogramming or telomerase 
activation during this process both in mice (Marion et al., 2009b) and humans (Suhr 
et al., 2009). KLF4 activates the expression of human TERT by binding to its 
promoter in cancer and ES cells (Wong et al., 2010). In mouse ES cells, recruitment 
of -catenin is necessary for Tert transcription and KLF4 promotes this binding 
(Hoffmeyer et al., 2012). Likewise, enhanced binding of OCT3/4 and NANOG has 
been described in the Terc locus in human iPS cells and murine ES cells (Agarwal et 
al., 2010). Nevertheless, it has been reported that mouse Tert gene expression is 
moderately increased during reprogramming in comparison with the human TERT, 
Figure 5: Kinetics of marker expression during reprogramming 
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whose transcription is strongly upregulated in this process (Mathew et al., 2010). 
Thus, post-translational mechanisms are also presumed to regulate telomerase 
activation during reprogramming. 
Telomerase activation during reprogramming triggers a telomere elongation 
both in mice and humans that takes place mainly post-reprogramming (Agarwal et 
al., 2010; Marion et al., 2009b). Mouse iPS cells show a moderate telomere 
elongation compared to parental fibroblasts at early passages (P8), but these length is 
progressively increased upon passages, achieving a telomere length similar to mouse 
ES cells (Marion et al., 2009b). Apparently, unlike the slow and progressive telomere 
elongation in mouse iPS cells, human iPS cell telomeres achieve the 14-15 kb length 
characteristic of human ES cells as early as P5 (Suhr et al., 2009). Telomerase 
activity and telomere length differ between humans and laboratory mice, which 
could explain the differences in telomerase activation and telomeres lengthening 
during the process of reprogramming between these two species. Nevertheless, it has 
become evident that iPS cells can exhibit heterogeneity in both telomerase activity 
and telomere length (Mathew et al., 2010; Suhr et al., 2009; Vaziri et al., 2010). 
While telomere elongation during reprogramming is mainly telomerase dependent, 
independent mechanisms like ALT have now been reported to be relevant for 
continuous self-renewal of iPS cells via the maintenance or extension of telomere 
length, contributing to the mentioned heterogeneity (Wang et al., 2012; Yehezkel et 
al., 2011). In fact, higher telomere recombination frequencies were observed in iPS 
cells and ES cells compared to differentiated MEFs (Marion et al., 2009b). It has 
been reported that not only telomere length but also telomere chromatin is altered 
during the reprogramming process. While telomeres in differentiated somatic cells 
are usually composed of heterochromatin, recent studies have shown that iPS and ES 
cells contain relatively “open” telomeric chromatin. It is likely that reprogramming 
allows the elongation of telomeres to a length characteristic of ESCs by making them 
more accessible for telomerase. Therefore, the telomeric chromatin of pluripotent 
stem cells is likely in a unique and dynamic state that can undergo remodeling during 
differentiation (Huang et al., 2014; Marion et al., 2009b; Wong et al., 2009). 
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In the last years, studies in pluripotent stem cells and during nuclear 
reprogramming based on the overexpression or deletion of components of telomerase 
have been crucial to unravel the link between telomeres and pluripotency. Both 
human and mouse ES and iPS cells with short telomeres due to Tert or Terc deletion 
show imparment of differentiation and loss of  pluripotency (Huang et al., 2011; 
Marion et al., 2009b; Pucci et al., 2013; Yang et al., 2008). In contrast, Tert 
overexpression in both mouse and human ES cells confers proliferative advantage, 
resistance to oxidative stress and enhanced differentiation (Armstrong et al., 2005; 
Yang et al., 2008). MEFs from increasing generation of Terc
-/- 
mice (G1 to G3) 
present a decrease in reprogramming efficiency that is restored by the reintroduction 
of telomerase (Marion et al., 2009b). Similarly, Tert
-/-
 tail-tip fibroblasts (TTFs) have 
recently been reported to show a reduced reprogramming ability independent of 
telomere shortening, suggesting extra-telomeric functions of TERT during this 
process (Kinoshita et al., 2014). IPS cell studies using fibroblasts from DC patients 
with mutations in different components of telomerase have also shed light on the 
interplay between telomerase and pluripotency establishment, highlighting the 
importance of telomere maintenance for the viability of iPS cells (Agarwal et al., 
2010; Batista et al., 2011). In contrast, TERT overexpression in human keratinocyte 
lines was described to enhance reprogramming efficiency, since it leads to 
immortalization of these cells (Utikal et al., 2009).  
In mice, TPP1 shelterin has been described to be necessary for telomere 
elongation by facilitating the recruitment of telomerase (Tejera et al., 2010). Alike 
TERT, TRF1 and TRF2 have also been characterized as stem cell markers, since they 
are overexpressed in ES or iPS cells (Ginis et al., 2004; Schneider et al., 2013). In 
particular, human TRF1 is one of the genes most consistently highly expressed in ES 
and iPS cells compared to the starting populations (Boue et al., 2010; Hosseinpour et 
al., 2013). High expression of TRF1 is associated with early stages of ES-cell 
generation (cultivated ICM cells) coincidental with high SOX2 and OCT3/4 levels 
and before telomere elongation (Varela et al., 2011). Recently, a publication from 
our lab showed that the reprogramming factor OCT3/4 binds directly to Trf1 
promoter, modulating its expression in pluripotent cells (Schneider et al., 2013). 
Besides, Trf1 is in the group of genes downregulated after Oct3/4 supression in 
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mouse ES cells (Sharov et al., 2008), highlighting the connection between TRF1 and 
stem cell biology. Knowing the relevance of telomere remodeling and maintenance 
during the acquisition of pluripotency, it becomes interesting to study the possible 
implications of shelterins during this process, as they have essential roles in telomere 
length regulation, protection and replication. 
  
Objectives
Objectives 
39 
 
 
 
1. Identification of putative extra-telomeric binding of TRF1 
 
1. To identify TRF1 binding sites in MEFs by ChIP- sequencing analysis 
  
2.  To address whether telomere shortening can influence TRF1 binding to extra-
telomeric regions by ChIP-sequencing. 
 
2. Dissecting reprogramming process: shelterin and telomerase during iPS cells 
generation 
 
1. To enlighten the role of TRF1 protein during the process of reprogramming by 
gain and loss of function experiments in MEFs during this process. 
 
2. To study the effect of Trf1 excision on mouse iPS cells. 
 
3. To analyze the effect of Tert overexpression on the acquisition of pluripotency 
by reprogramming to iPS cells. 
 
4. To unveil the dynamics of shelterins and telomerase during reprogramming.
  
  Objetivos
Objetivos 
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1. Identificación de lugares de unión de TRF1 extra-teloméricos. 
 
1. Identificar lugares de unión de TRF1 en MEFs mediante la técnica de ChIP-
sequencing 
 
2. Averiguar si el acortamiento telomérico puede influir en la unión a regiones 
extra-teloméricas de TRF1 mediante ChIP-sequencing 
 
 
2. El proceso de reprogramación: shelterinas y telomerasa durante la 
generación de células iPS 
 
1. Elucidar el papel de la proteína TRF1 durante el proceso de reprogramación 
por medio de experimentos de ganancia o pérdida de función en MEFs 
durante este proceso 
 
2. Estudiar el efecto de la escisión de Trf1en células iPS de ratón 
 
3. Analizar el efecto de la sobreexpresión de Tert en la adquisición de 
pluripotencia mediante reprogramación a células iPS 
 
4. Desvelar la dinámica de expresión de shelterinas y telomerasa durante la 
reprogramación 
  
 Experimental Procedures
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1. Culture conditions 
Cells were maintained in an incubator at 37ºC with 16% O2 and 5% CO2. 
Mouse Embryonic Fibroblasts (MEFs) and HEK293T cells (ATCC® Number CRL-
11268™) were cultured in Dulbecco’s Modified Eagle’s medium (DMEM; Gibco) 
supplemented with 10% heat inactivated fetal bovine serum (FBS, Gibco) and 1% 
antibiotic/antimycotic (Gibco). iPS cells were grown in iPS medium ( high-glucose 
DMEM (Invitrogen) supplemented with 15% Knockout Serum Replacement (KSR; 
Gibco, 10828028), Leukemia Inhibitory Factor (LIF, 1000 U/ml; ESGROTM, 
Millipore ESG1107),  non-essential aminoacids (MEM Non-Essential Aminoacids 
Solution; 1X; Invitrogen), -mercaptoethanol (0.5 mM; Invitrogen), 
Penicillin/Streptomycin (1X; Gibco) and Glutamax (Gibco) on feeders or gelatin 
coated plates. 
 
2. Extraction and culture of MEFs 
MEFs were isolated from 13.5 embryos. Uterus was removed and put into PBS 
with antibiotic/antimycotic at 37ºC. Embryo’s head and guts were taken out and the 
head was used for genotyping. The embryo was minced with a razorblade in 0.1% 
trypsin (10X diluted in PBS; Invitrogen) and incubated for 20 min at 37ºC, dispersed 
with a Pasteur pipette and incubated for another 20 min. Cells were transferred to a 
10 cm-diameter dish and grown with 10 ml of the aforementioned medium. 
MEFs of the following genotypes were isolated: C57BL/6 wild-type,  p53
-/-
, 
Terc
-/-
  of first and third generation G1 and G3) (Blasco et al., 1997), Trf1
lox/lox 
p53
-/- 
and Trf1
+/+
p53
-/-
 (Martinez et al., 2009), Trf1
lox/lox 
Cre-ERT2
+/ki 
(Trf1
lox/lox
 RERT
n
) 
and  Trf1
+/+ 
Cre-ERT2
+/ki
 (Trf1
+/+
 RERT
n
)  and Rosa26:rtTA; tet-O-Fug-OSKM (i4F) 
(Abad et al., 2013). 
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3. Retroviral and lentiviral infections 
Retroviral supernatants were produced in HEK293T cells (5 x 10
6
 cells per 100 
mm-diameter dish) transfected with the ecotropic packaging plasmid pCL-Eco (4 g) 
together with either one of the following constructs (4 g):  pBabe-GFP, pBabe-Cre, 
pBabe-EV, pBabe-Trf1, pMXs-Oct3/4 (Addgene, plasmid 13366), pMXs-Sox2 
(Addgene, plasmid 13367), pMXs-Klf4 (Addgene, plasmid 13370) or pMXs-c-
Myc (Addgene, plasmid 13375). Transfections were performed using Fugene-6 
transfection reagent (Roche) according to the manufacturer’s protocol. For infections 
with Cre recombinase, Trf1
lox/lox 
p53
-/-
 and Trf1
+/+ 
p53
-/-
 MEFs were seeded the 
following day (2 x 10
6
 cells per 150 mm-diameter dish) and infected after 24 hours 
with the diluted retroviral supernatants (2:5). Infected cells were selected by addition 
of puromycin (2 g/ml, Sigma) after 48 h. For ChIP-seq experiment, Trf1/ p53-/--
Cre and Trf1
+/+ 
p53
-/-
-Cre MEFs were amplified and maintained in puromycin 
selection for one week before cross-linking. 
Lentiviral supernatants were produced in HEK293T cells transfected with the 
packaging plasmids pLP1 (1.95 µg), pLP2 (1.3 µg), pLP/VSVG (1.65 µg) 
(Invitrogen), and either one of the following lentiviral constructs (5 µg), pLKO.1-
puro-scramble shRNA (Addgene), pLKO.1-puro-shTrf1 (bacterial glicerol stock 
TRCM0000071298, Sigma-Aldrich), pLVX-EV (Clontech), pLVX-Tert or pLVX-
Tpp1.  
 
4. PCR 
Trf1
+/+
p53
-/- 
and Trf1
lox/lox
 p53
-/-
 were genotyped by PCR with the following 
primers: E1-F2 (Forward, 5’-GGATGCTCGACTTCCTCT-3’) and SA1 (Reverse, 
5’-GCTTGCCAAATTGGGTTGG-3’) for Trf1 genotyping and p53F-12B7 (5’-
TGGTTTGTGCGTCTTAGAGACAGT-3’),p53R-1B3 (5’-
AAGGATAGGTCGGCGGTTCAT-3’) and pPNTF-2B5 (5’-
CCAGCTCATTCCTCCCACTCA-3’) for p53 genotyping. The removal of exon 1 of 
Trf1 in Trf1
lox/lox 
MEFs upon retroviral infection with Cre recombinase and in iPS 
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cells obtained from Trf1
/
 p53
-/-
 -Cre MEFs was checked by PCR with E1-Popout 
(Forward, 5’-ATAGTGATCAAAATGTGGTCCTGGG-3’) and SA1 (Reverse, 5’-
GCTTGCCAAATTGGGTTGG-3’) primers as previously described (Martinez et al., 
2009). 
I4F MEFs were genotyped by three different PCR reactions. Rosa26-rtTA 
insertion in MEFs was confirmed with primers 125B (5´-
AAAGTCGCTCTGAGTTGTTAT-3’) and 126B (5’-
GCGAAGAGTTTGTCCTCAACC-3’) rendering a band of approximately 300 bp, 
while Rosa26-wt allele was confirmed with 125B and 127B (5’-
GGAGCGGGAGAAATGGATATG-3’) primers, rendering a band of around 500 bp. 
The Tet-O-FUW-OSKM insertion was confirmed by PCR with the following 
primers: ORF2-Fw (5’-GGATGGAGTGGGACAGAGAA-3’) and ORF2-Rv (5’-
GTGCCGATCCGTTCACTAAT-3’), which renders a fragment of 378 bp. 
 
5. Taqman qPCR 
Trf1
lox/lox 
RERT
n
 and Trf1
+/+
 RERT
n
 MEFs were genotyped by Transnetyx 
company using a qPCR based system and Taqman® probe technology with the 
following primers and probes (Table 1).  
Table 1: Primers and probes used for Taqman qPCR genotyping 
Allele Primer and Probe Sequence 5’ 3’ 
Cre 
Fw: TTAATCCATATTGGCAGAACGAAAACG 
Rv: CAGGCTAAGTGCCTTCTCTACA 
Probe: CCTGCGGTGCTAACC 
Trf1

 
Fw: GCTATACGAAGTTATTCGAGGTCGAT 
Rv: GGTGGCGGCCGAAGT 
Probe: CTCTAGAAAGTATAGGAACTTC 
Trf1
lox
 
Fw: GCTATACGAAGTTATTCGAGGTCGATC 
Rv: TGTTTTGCCAAGTTCTAATTCCATCAGA 
Probe:  CCGTCGAGGAAGTTC 
Trf1
+
 
Fw: GAGACGGCGCGAAACC 
Rv: GCGGGAGCCAGGACTTC 
Probe: CCGCTTCCTGTTTGCTG 
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6. Protein extracts and Western blot 
Total and nuclear protein extracts were used for Western blot analysis. To 
prepare nuclear extracts, the cell pellets were lysed by hypotonic buffer  A (10 mM 
Hepes-KOH [pH 7.9], 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA and protease 
inhibitors) by gentle pipetting. The cells were incubated on ice for 15 min, 25 l of 
10% NP-40 were added and cells were vigorously vortexed for 15 sec. Nuclei were 
collected by centrifugation (1 min; 14,000 rpm; 4°C) and gently resuspended in 
nuclear extraction buffer B (20 mM HEPES [pH 7.9], 25% glycerol, 0.4 M NaCl, 0.1 
mM EDTA, 0.1 EGTA and protease inhibitors). The samples were vigorously rocked 
at 4ºC for 15 min and centrifuged (5 min; 14,000 rpm; 4°C). For total extracts 
preparation we resuspended pellets in RIPA buffer and protease inhibitors, incubated 
the cells on ice for 30 min and sonicated them for 5 min. Total extracts were 
collected by centrifugation (15 min; 14,000 rpm; 4ºC). Protein concentration was 
determined using Bradford assay (Sigma) for nuclear extracts or Bio-Rad DC protein 
assay for total extracts. 30 g of protein per extract were loaded in a NuPAGE 4-
12% Bis-Tris gel 1.0 mm (Invitrogen) and electrophoresed in MES SDS Running 
Buffer (Invitrogen) before Western blotting. The following antibodies were used: 
mouse anti-TRF1 (Abcam; ab-10579; 1:1000), mouse anti--actin (Sigma; a2228; 
1:10,000), rabbit anti-SMC1 (Bethyl Laboratories; # A300-055A; 1:1000). 
 
7. ChIP assays and telomere dot-blots 
Chromatin Immunoprecipitation (ChIP) were carried out essentially as 
described previously (Garcia-Cao et al., 2004), with some modifications. We cross-
linked the cells by adding formaldehyde (Sigma) directly to tissue culture medium to 
a final concentration of 1% and incubated cultures for 15 min at RT on a shaking 
platform. We stopped the cross-linking by adding glycine to a final concentration of 
0.125 M and incubated the cells for 5 min. We washed cross-linked cells twice with 
cold PBS, scrapped, centrifuged (4,000 rpm; 5 min; 4ºC) and resuspended them with 
lysis buffer (1% SDS, 50 mM Tris-HCl [pH 8.0] and 10 mM EDTA and protease 
inhibitors) at a density of 20 × 10
6
 cells/ml for 10 min on ice. We sonicated lysates to 
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obtain chromatin fragments <1 kb and centrifuged them for 15 min in a 
microcentrifuge at RT. We sonicated each sample for 50 min using the Bioruptor 
sonication system (Diagenode) in order to shear the DNA into small fragments. 
Chromatin from 4 x 10
6
 cells was used per immunoprecipitation. We diluted 400 μl 
of lysate 1:10 with dilution buffer (1.1% Triton X-100, 0.01% SDS, 1.2 mM EDTA 
[pH 8.0], 167 mM NaCl and 16.7 mM Tris-HCl [pH 8.0] and protease inhibitors). 
We pre-cleared each immunoprecipitation with 50 l of protein A/G Plus agarose 
beads (Santa Cruz Biotechnology, sc-2003) for 1 h and incubated with 4 l of rabbit 
polyclonal anti-mouse TRF1 serum antibody (generated in our laboratory) (Garcia-
Cao et al., 2004) or preimmune serum at 4ºC o/n on a rotating platform. We then 
added 50 l of protein A/G Plus agarose beads and incubated for 1 h. We washed the 
immunoprecipitated pellets with low salt immune complex wash buffer (0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0] and 150 mM NaCl) (one 
wash), high salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl [pH 8.0] and 500 mM NaCl) (one wash), LiCl immune 
complex wash buffer (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM 
EDTA and 10 mM Tris-HCl [pH 8.0]) (one wash) and TE buffer (10 mM Tris-HCl 
[pH 8.0] and 1 mM EDTA) (two washes). We then eluted the chromatin from the 
beads twice by incubation with 250 μl of elution buffer (1% SDS and 50 mM 
NaHCO3) during 15 min at RT with rotation. After adding 20 μl of 5 M NaCl, we 
reversed the cross-links for 4 h at 65 °C. Samples were supplemented with 20 μl of 1 
M Tris-HCl [pH 6.5], 10 μl of 0.5 M EDTA, 20 μg of RNase A and 40 μg of 
proteinase K and incubated for 1 h at 45 °C to remove RNA and proteins. Inputs 
correspond to the total DNA sample, 1:10 dilution of the amount of lysate used in the 
immunoprecipitation. After phenol/chloroform DNA extraction, the precipitated 
DNA was eluted and transferred to a Hybond+ membrane by dot-blotting. The 
membrane was then hybridized with either a telomeric probe recognizing TTAGGG 
repeats or a probe recognizing major satellite sequences, characteristic of pericentric 
heterochromatin. 
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8. ChIP-sequencing 
For each sample we used around 100 x 10
6 
cells. Each sample was 
independently processed into sequencing libraries with a ChIP-Seq sample 
preparation kit (Illumina) in accordance with the manufacturer's instructions (Quail 
et al., 2008).  Input samples from Trf1
+/+
 p53
-/-
-Cre
 
 and Trf1
/ 
p53
-/-
-Cre
 
MEFs were 
pooled
  
in a single library (input pool 1) and inputs from wild-type, Terc
-/-
 G1 and 
Terc
-/- 
G3 MEFs in another library (input pool 2). 29, 37, 40, 16, 15, 26 and 40 ng of 
DNA (as quantitated by PicoGreen Fluorometry) were respectively used for Trf1
+/+
 
p53
-/-
-Cre, Trf1
/ 
p53
-/-
-Cre, input pool 1, wild-type, Terc
-/- 
G1, Terc
-/-
 G3 and input 
pool 2 samples. Each sample was electrophoresed on agarose gel and a fraction of 
100-150 bp was taken. Extracted DNA was processed through subsequent enzymatic 
treatments of end-repair, dA-tailing, and ligation to adapters as in Illumina's "ChIP 
Sequencing Sample Prep Guide" (part # 11257047 Rev. A), with the exception that 
no further gel extraction was performed. Adapter-ligated library was PCR amplified 
with Illumina PE primers. The resulting purified DNA libraries were applied to an 
Illumina flow cell for cluster generation and sequenced on a Genome Analyzer IIx 
(GA2) by following manufacturer's protocol and using 40 (first ChIP-seq 
experiment) or 42 (second experiment)-base read run.  
 
9. ChIP-sequencing data analysis 
Image analysis was performed with Illumina Real Time Analysis software 
(RTA1.8 for Trf1
/ 
p53
-/-
-Cre, Trf1
+/+
 p53
-/-
 -Cre and input pool 1 samples and 
RTA1.6  for wild-type, Terc
-/-
 G1, Terc
-/- 
G3 and input pool 2 samples). Sequence 
alignment to the reference genome (NCBI m37/mm9 mouse assembly, April 2007, 
strain C57BL/6J) was made with Illumina's ELANDv2 algorithm on its 
"eland_extended" mode from CASAVA-1.7 package. ELANDv2 performs multiseed 
alignment with consecutive read substrings of 16 to 32 bases separately. The seeds 
are aligned to multiple candidate positions in the reference genome, with a maximum 
of two mismatches allowed per 32 bases seed; then they are extended to the full read 
using gapped alignment, allowing for any number of mismatches and potential gaps 
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(indels) of up to 20 bases. The best alignment among the multiple candidate positions 
is chosen based on quality scores. Uniquely aligned 40 or 42-bp-length reads were 
pooled into seven datasets: Trf1
+/+
 p53
-/-
-Cre, Trf1
/ 
p53
-/-
-Cre, input pool 1, wild-
type, Terc
-/- 
G1 and Terc
-/-
 G3 and input pool 2. Peak detection was performed with 
MACS version 1.4 software (p value= 1 x 10
-5
; FDR= 10%; 300 bp window). 
 
10. Validation of ChIP-seq results by qRT-PCR 
For ChIP-seq validation, quantitative real-time PCR (qRT-PCR) was 
performed using an ABI PRISM 7700 thermocycler (Applied Biosystems) and the 
Power SYBR Green PCR Master mix (Life technologies) according to the 
manufacturer’s protocol. Immunoprecipitated and input DNA from independent 
ChIP experiments in Trf1
+/+
 p53
-/-
 -Cre and Trf1
/ 
p53
-/-
-Cre samples were 
quantified by qRT-PCR with oligos designed to amplify DNA fragments 
corresponding to the following peaks: 603 (chr2: 28,039,717- 28,040,535), 620 
(chr2: 57,481,892- 57,482,277), 874 (chr6: 52,133,777- 52,134,592), 980 (chr8: 
73,956,797- 73,957,467), 1073 (chr9: 95,326,167- 95,326,779), 804  (chr4: 
153,217,553- 153,218,190), 805 (chr4: 154,765,741- 154,766,224), 806 (chr4: 
155,161,073- 155,161,670), 807 (chr4: 155,334,959- 155,335,528), 1014 (chr8: 
128,849,051-128,849,629), 1015 (chr8: 129,108,238- 129,108,707) and 1016 (chr8: 
129,423,259- 129, 423,839). The primer sequences are listed in Table 2. The results 
were normalized to the value obtained in the input DNA, by calculating de Ct 
values between the levels obtained in input DNA and that of the precipitated DNA. 
The results were relativized to wild-type levels. All values were obtained in 
triplicates.  
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Table 2: Sequences of primers used for ChIP-qPCR experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11. Preparation of feeders 
Primary wild-type B6 MEFs were expanded up to passage 4-5 and grown to 
confluence. After washing, cells were trypsinized and pelleted by centrifugation 
(1,200 rpm; 5 min). Cell pellets were irradiated at 80 greys and frozen in aliquots of 
Name Sequence 5' 3' 
Peak603-Fw AACCCTAACCCCAACCCTAA 
Peak603-Rv GAGGCCAAGTCAGGTTCATC 
Peak620-Fw GGGTTAGGGTTAGGGTTAGGG 
Peak620-Rv CACAGAAGTGGATGCTCACAG 
Peak874-Fw GGCAGCAGACCACAACCT 
Peak874-Rv AGGGTTAGAGGGTTAGGG 
Peak980-Fw TATGGGCCTGTTAGGGTTAGG 
Peak980-Rv CACACACCAAAGTTAAATCAAGAGC 
Peak1073-Fw TGGACTTAGTGCAGCCAATG 
Peak1073-Rv TCAGTTTTCCAAGGGTTAGGG 
Peak804-Fw GGGGAAGTCGGGCTTCTCTAT 
Peak804-Rv TCATGCCTGTCCATCTGTCCT 
Peak805-Fw TAACTTTGGGCATGGTCTCCA 
Peak805-Rv AGAGGAGCAGAGCCAGGTAGGT 
Peak806-Fw TGCTGAGCCATTTCTCTAGGC 
Peak806-Rv CAGAGGCAGGTGGATTTCTGA 
Peak807-Fw TGAGTCCATCCCTAGCCACAA 
Peak807-Rv CAAAGATGCAGCACCCTGTTC 
Peak1014-Fw GGGCTCCAGCAAATGAGGTAG 
Peak1014-Rv TTTCCTGATGCCTATCGCTGA 
Peak1015-Fw ACGAGGCGAGTTCAATTCCAT 
Peak1015-Rv GGGCTCTTCCTTTTCCCCTTT 
Peak1016-Fw GAGTCACGCATACCCCTCCTT 
Peak1016-Rv TGACCTGTCCTGTGAGGTGGT 
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5 x 10
6 
cells. Plates were pre-coated with gelatin and feeders were seeded the day 
before culturing the iPS cells. 
 
12. Cloning 
Mouse Trf1 cDNA was obtained in Addgene (pBluescript SK +/- -mTrf1, 
plasmid 12303). Trf1 cDNA was cut from pBluescript plasmid by digest with 
EcoRI and XhoI restriction enzymes and treated with Mung Bean nuclease to obtain 
blunt ends. It was then cloned in pBabe-puro-EV retroviral backbone, previously 
linearized with SnabI. Sequence was confirmed with pBabe-Fw (5’-
AAGCCCTTTGTACACCCTAAGC-3’) and pBabe-Rv (5’- 
GGACTTTCCACACCTGGTTGC-3’) primers. 
Mouse Tpp1 cDNA was obtained by PCR with the following primers: 
Tpp1cDNA-Fw (5’-ATATACGTAATGTCCGATTCAGGGTTGCT-3’) and 
Tpp1cDNA-Rv (5’- ATAGAATTCTCATACCTGGGTTAACTCAG-3’) and 
ensuing digest. The resulting PCR product was gel purified, ligated with the 
linearized pLVX-puro-EV lentiviral backbone and transformed into DH5 
Escherichia coli cells. Individual clones were sequenced. 
 
13. Reprogramming  and  maintenance of iPS cells 
One day after seeding (2 x 10
5
 MEFs per 35 mm-diameter dish), MEFs were 
infected four times (twice a day) with a cocktail of the three or four retroviral 
Yamanaka factors pMXs-Oct3/4, pMXs-Sox2, pMXs-Klf4 and pMXs-c-Myc (OSK 
or OSKM cocktails). The following day, medium was changed to iPS cell medium, 
which was changed daily for around two weeks until the appearance of iPS colonies. 
iPS colonies were picked 2-3 weeks after infection and expanded on feeder 
fibroblasts. iPS medium was changed daily and at 70-80 % of confluence cells were 
trypsinized and passed onto a new dish with a 1:5 dilution.  
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Trf1 KO MEFs: Trf1
lox/lox
p53
-/-
 and Trf1
+/+
p53
-/-
 MEFs were infected once 
with retroviral Cre recombinase, selected and reprogrammed one week after Cre 
infection, as described above. Colonies obtained from Trf1
/
 p53
-/-
- Cre MEFs were 
picked 2-3 weeks after infection and expanded on feeder fibroblasts. Trf1 deletion in 
these iPS cells was checked by PCR with primers E1-popout and SA1. 
Trf1 KD MEFs: For the reprogramming of Trf1 KD cells, p53
-/- 
MEFs were 
used. The following viral cocktails were used: pBabe-EV and pLKO.1-puro-
scramble (mock-scramble), pBabe-EV and pLKO.1-puro-shTrf1 (mock-shTrf1), 
OSK and pLKO.1-puro-scramble (OSK-scramble), OSK and pLKO.1-puro-shTrf1 
(OSK-shTrf1). After 4 infections, medium was replaced by iPS medium with 
puromycin to select for the shRNA vectors. Cultures were maintained in the presence 
of drug selection with daily medium changes.  
Trf1 conditional KO MEFs: we reprogrammed Trf1
lox/lox 
RERT
n
 and Trf1
+/+ 
RERT
n
 MEFs as described above. Trf1 excision in the resultant iPS cells is explained 
in section 15. 
Trf1 overexpressing MEFs: we infected wild-type MEFs with the three 
reprogramming factors (OSK) in combination with either pBabe-puro-EV or pBabe-
puro-Trf1. Infected MEFs were maintained in puromycin selection during 
reprogramming. For the Yamanaka factors replacement assay, we infected at the 
same time with two of the factors (OK, OS or SK) in combination with either pBabe-
puro-EV or pBabe-puro-Trf1 and waited around 1 month for the appearance of 
colonies, changing the iPS medium every 2 days. 
Tert and/or Tpp1 overexpressing MEFs: wild-type MEFs were infected with 
different combinations of retroviral and lentiviral viruses: OSK + pLVX-EV, OSK + 
pLVX-Tert, OSK + pLVX-Tpp1, OSK + pLVX-Tert + pLVX-Tpp1, OSKM + 
pLVX-EV, OSK + pLVX-Tert, OSK + pLVX-Tpp1, OSK + pLVX-Tert + pLVX-
Tpp1.  
Reprogrammable i4F MEFs: 5 x 10
5
 i4F MEFs were plated in gelatin-coated 
35 mm-diameter dishes. The following day the i4F cassette was activated by 
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doxycycline (1 g/ml). Medium was changed every day until iPS cell colonies 
appeared after approximately one week. 
 
14. Reprogramming efficiency 
 The infection efficiency during reprogramming was determined by measuring 
the percentage of GFP
+
 cells after infection with pBabe-GFP. Cells infected with 
OSK or OSKM + pBabe-GFP were trypsinized at day 2 post-infection, washed with 
PBS and resuspended in 300 l of PBS for flow cytometry analysis in FACSCalibur 
(BD Biosciences). TO-PRO-3 dye was added to the cells to stain for dead cells. Pulse 
processing was used to exclude cell aggregates and debris. At least 20,000 events 
were collected per sample. Data was analyzed using FlowJo Software v.9.1 (Treestar, 
Eugene, OR). Reprogramming efficiency was determined by alkaline phosphatase 
(AP) activity (AP detection kit, Chemicon International or AP Blue Membrane 
Solution, Sigma-Aldrich), following the manufacturer’s instruction. After around of 
reprogramming AP
+
 colonies were counted and the results were normalized to the 
respective efficiencies of retroviral infection.  
 
15. Trf1 excision in iPS cells 
We reprogrammed Trf1
lox/lox
 and Trf1
+/+
 RERT
n
 as described above. The 
resulting iPS cells were picked and clones of each genotype were used for the 
treatment with 4-hydroxytamoxifen (4-OHT; Sigma-Aldrich), in order to obtain 
Trf1
/ 
and Trf1
+/+
 iPS cells, respectively. The iPS from both genotype were seeded 
at low density (50,000 cells per 35 mm-diameter dish) in feeders or gelatin coated 
(for qRT-PCR analysis) dishes and treated with 4-OHT at a final concentration of 0.2 
M in complete iPS medium, which was replaced every day.  
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16. SSEA-1 staining 
 SSEA-1 expression during reprogramming was assessed by flow cytometry, as 
described elsewhere (Li et al., 2009). 2 x 10
5
 seeded cells were used for each assay.  
Cells were trypsinized and washed once with PBS. A second wash was done with 
PBS/0.5% BSA (Sigma) before incubation with the antibody. Cells were incubated 
with 10 l of anti-human/anti-mouse APC-conjugated SSEA-1 antibody (R&D) in 
50 l of PBS-0.5% BSA for 30 min at 4ºC. Afterwards, cells were washed by PBS-
0.5% BSA once to remove antibody and resuspended in 300 l of PBS for flow 
cytometry analysis. Cells were stained with DAPI to exclude for dead cells. Samples 
were analyzed on the BD LSRII Fortessa cell analyzer (BD Biosciences) using pulse 
processing to exclude cell aggregates and debris. At least 20,000 events were 
collected per sample. Data was analyzed using FlowJo Software v.9.1 (Treestar, 
Eugene, OR). 
 
17.  Apoptosis assay 
At day 0 (Ctrl), 3 and 6 of 4-OHT treatment  iPS cells were collected, washed 
in PBS, resuspended in 1X annexin V binding buffer (BD Biosciences) and stained 
with FITC annexin V (BD Biosciences). Cells were incubated for 15 min in the dark 
at RT. DAPI was added to discriminate dead cells. Apoptotic cells (Annexin V
+
, 
DAPI
-
 cells) were quantified using the BD FACSCanto system (BD Biosciences), 
using pulse processing to exclude cell aggregates and debris. At least 20,000 events 
were collected per sample. Data was analyzed using FlowJo Software v.9.1 (Treestar, 
Eugene, OR). 
 
18. Immunofluorescence 
At day 0, 3 and 6 of 4-OHT treatment iPS cells were collected and plated in 
glass bottom dishes (24 well plates; MatTek) with feeders. Cells were fixed in 4% 
paraformaldehyde (PFA) in PBS for 15 min at RT, permeabilized twice in 0.1% 
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Triton X-100/PBS for 15 min and blocked with 100% Australian FBS (Genycell) for 
1 h at RT. Samples were incubated o/n at 4ºC with primary antibodies for TRF1 
(rabbit polyclonal home-made antibody; 1:500) and H2AX (Upstate Biotechnology; 
1:500) in diluents with background reducing agents (Invitrogen). Secondary antibody 
incubation (1 h; RT) was performed after 3washes of 5 min each with PBS. The 
nuclei were counterstained in a 4 μg/ml DAPI/PBS solution for 10 min before 
mounting with Vectashield (Vector Laboratories).  
 
19. RNA extraction, cDNA synthesis and qRT-PCR 
 Total RNA from reprogramming cells at days 9, 11 and 14 was extracted with 
Trizol (Invitrogen). Samples were treated with DNAse I (DNA free kit; Ambion). 
Reverse transcription was carried out using Ready-To-Go You-Prime First-Strand 
Beads kit (GE Healthcare) with random primers (Invitrogen) or iScript Advanced 
cDNA synthesis kit (Bio-Rad) according to the manufacturer’s protocols. qRT-PCR 
was performed using DNA Master SYBR Green mix (Applied Biosystems) and 7500 
Fast Real-time PCR System (Applied Biosystems) according to the manufacturer`s 
instructions. Primers used are listed in Table 3. All values were obtained in 
triplicates. Calculations were made using the Ct method as described in (Yuan et 
al., 2006), using Gapdh as reference gene. The values were normalized to WT levels.  
 
20. Q-FISH 
 In order to analyze telomeric aberrations, cells were arrested in metaphase by 
treatment with colcemid (0.1 g/ml; Gibco) for 3 h at 37ºC. Cells were swollen in 
hypotonic buffer (10 mM Tris-HCl [pH 7.5], 10 mM NaCl, 5 mM MgCl2), fixed with 
methanol/acetic acid as described elsewhere (Samper et al., 2000) and dropped onto 
slides. Slides were washed in PBS and further fixed in 4% formaldehyde/PBS for 2 
min followed by a 3 x 5 min washing step with PBS.  Slides were incubated in 0.1% 
porcine pepsine (Sigma), 0.01 M HCl (Merck) for 10 min at 37°C, washed with PBS 
and another fixing and washing step was performed. After dehydratation in 70%, 
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90% and 100% ethanol dilutions, slides were further air dried and the Q-FISH 
labelling probe mix (10 mM Tris, 25 mM MgCl, 9 mM citric acid, 82 mM Na2HPO4 
[pH 7], 70% deionised formamide (Sigma), 0.25% blocking reagent (Roche) and 0.5 
µg/ml Telomeric PNA-probe) was applied. Telomeric PNA-probe was generated at 
Panagene directed against telomeric repeats. The PNA sequence is Cy3-00-
CCCTAACCCTAACCCTAA-Lys. Slides were further covered with a coverslip and 
the DNA was denatured on a pre-warmed heating plate at 85°C for 3 min. Slides 
were then incubated for 3 h in a wet chamber at RT , followed by a 2 x 15 min 
washing step in 70% formamide, 10 mM Tris and 0.1% BSA (Sigma). After another 
2 x 15 min of washing with 0.08% Tween20 (Sigma)/TBS slides were incubated in a 
4 µg/ml DAPI (Sigma) solution and mounted with Vectashield. Around 40 
metaphases per genotype from a total of two independent iPS clones per genotype 
were scored for chromosomal aberrations by superimposing the telomere image on 
the DAPI chromosomes image. 
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
Table 3: Sequences of primers used for qRT-PCR experiments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Sequence 5' 3' 
Nanog-Fw AGGGTCTGCTACTGAGATGCTCTG 
Nanog-Rv CAA CCA CTG GTT TTT CTG CCA CCG 
Oct3/4-Fw TCTTTCCACCAGGCCCCCGGCTC 
Oct3/4-Rv TGCCGGGCGGACATGGGGAGATCC 
Tert-Fw GGATTGCCACTGGCTCCG 
Tert-Rv TGCCTGACCTCCTCTTGTGAC 
Terc-Fw TCATTAGCTGTGGGTTCTGGT 
Terc-Rv TGGAGCTCCTGCGCTGACGTT 
Trf1-Fw TCTAAGGATAGGCCAGATGCCA 
Trf1-Rv CTGAAATCTGATGGAGCACGT 
Trf2-Fw AGAGCCAGTGGAAAAACCAC 
Trf2-Rv ATGATGGGGATGCCAGATTA 
Tin2-Fw TGCCCTGAAGCATCACTTCC 
Tin2-Rv GGCAACTAGAAAGGATTCCCC 
Rap1-Fw AAGGACCGCTACCTCAAGCA 
Rap1-Rv TGTTGTCTGCCTCTCCATTC 
Tpp1-Fw ACTTGTGTCAGACGGAACCC 
Tpp1-Rv CAACCAGTCACCTGTATCC 
Pot1a-Fw AAACTATGAAGCCCTCCCCA 
Pot1a-Rv CGAAGCCAGAGCAGTTGATT 
Pot1b-Fw AGTTATGGTCGTGGGATCAGAG 
Pot1b-Rv GAGGTCTGAATGGCTTCCAA 
Gapdh-Fw TTCACCACCATGGAGAAGGC 
Gapdh-Rv CCCTTTTGGCTCCACCCT 
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1. Identification of putative extra-telomeric binding of TRF1 
1.1. Restricted binding of TRF1 to telomeres in MEFs 
Several studies in the last years have reported binding of shelterins to extra-
telomeric DNA regions in a variety of species. TRF1 is a component of the shelterin 
complex that binds to dsDNA at telomeres by recognition of 5'-YTAGGGTTR-3' 
sequences through its C-terminal SANT/MYB DNA-binding domain. However, this 
protein has also been implicated in protection of Interstitial Telomeric Sequences (ITSs) 
in humans and Chinese hamster (Bosco and de Lange, 2012; Krutilina et al., 2003; 
Simonet et al., 2011). Recent studies reported that TRF1 protein is able to bind to extra-
telomeric sites of the genome, most of them ITSs, in human cell lines (Bosco and de 
Lange, 2012; Simonet et al., 2011). Furthermore, TRF1 is involved in protection of 
ITSs from breaks and chromosome rearrangements in Chinese hamster cells, which 
contain long blocks of het-ITSs representing about 5% of the genome (Day et al., 1998; 
Krutilina et al., 2001; Krutilina et al., 2003). Together, these data suggest that mouse 
TRF1 could also show in vivo extra-telomeric binding and have crucial roles in genome 
stability.  
To address this, we performed a whole-genome ChIP-sequencing (chromatin 
immunoprecipitation (ChIP) coupled with high-throughput sequencing) analysis.  We 
took advantage of the conditional Trf1
 
knockout mouse model from our lab, the 
Trf1
lox/lox 
mice (Martinez et al., 2009), to obtain Trf1-null MEFs that could be use as a 
negative control for TRF1 peak specificity. In this model, Trf1 gene exon 1 (E1) is 
flanked by two loxP sites and is excised upon Cre recombinase addition (Fig. 6A). The 
resulting Trf1
/
-Cre MEFs fail to proliferate due to a rapid induction of senescence, 
which is bypassed by canceling of the p53 and RB pathways. As for ChIP-seq 
experiments we needed a huge number of cells, we used p53-null MEFs for both Trf1
+/+
 
and Trf1
lox/lox 
genotypes, as p53 deficiency rescues cell proliferation in Trf1-null MEFs. 
We infected Trf1
+/+
 p53
-/-
 and Trf1
lox/lox
 p53
-/- 
MEFs with a retroviral vector carrying the 
Cre recombinase (pBabe-puro-Cre) once, amplified and selected them with puromycin 
for one week. Trf1 excision in Trf1
/ 
p53
-/-
-Cre was checked by PCR (Fig. 6B) and the 
decrease in TRF1 protein was confirmed by Western blot (Fig. 6C). 
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We next tested our home-made rabbit polyclonal antibody against full-length 
mouse TRF1 protein (Garcia-Cao et al., 2004) for its ability to pull down TRF1 protein 
in MEFs by dot-blot analysis after ChIP in Trf1
+/+
p53
-/-
-Cre and Trf1
/ p53
-/-
-Cre 
MEFs. As shown in Fig. 7, the antibody was able to specifically immunoprecipitate 
TRF1, which is bound to telomeric but not centromeric DNA. “No ab” corresponds to 
the DNA obtained from immunoprecipitation (IP) without antibody, with the 
preimmune-serum. Input DNA sample corresponds to the sheared chromatin before 
incubation with the anti-TRF1 antibody. 
 
 
Figure 6: Trf1 deletion in Trf1
lox/lox 
p53
-/-
 MEFs. (A) Scheme of the Trf1
lox
 allele. (B) Trf1 
deletion in Trf1
/ 
p53
-/-
 -Cre infected MEFs was confirmed by PCR. (C) Western blot analysis 
demonstrating the decrease in TRF1 protein upon infection with retroviral Cre recombinase.  
A 
B C 
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Factors such as GC content, read mappability, DNA repeats, copy number 
variations and local chromatin structure can influence sequencing and read distribution 
at different locations in the genome (Feng et al., 2012). Therefore, input DNA was used 
as a sequencing control sample of sonicated chromatin to eliminate background and to 
identify reliable read-enriched regions by ChIP-seq.  Illumina Genome Analyzer IIx was 
used for the high-throughput sequencing. The enrichment in telomeric repeats was 
corroborated before alignment with the mouse genome by the strong over-representation 
of raw 40 bp sequences containing the telomeric (TTAGGG)5 or the complementary 
(CCCTAA)5 repeats in Trf1
+/+
 p53
 -/-
-Cre MEFs compared to that in Trf1-null control 
(Trf1
/ p53
-/-
-Cre MEFs) (7-fold increase in both (TTAGGG)5  and (CCCTAA)5 
repeats) and the input DNA (input pool 1), which is a combination of inputs from 
Trf1
+/+
 p53
 -/-
-Cre and Trf1
/ p53
-/-
-Cre samples  (28-fold increase for (TTAGGG)5 
repeats and 34-fold increase for (CCCTAA)5 repeats) (Fig. 8). The enrichment in reads 
containing 2, 3, 4 and 6 repeats of the TTAGGG or CCCTAA sequences was also 
Figure 7: ChIP experiment with TRF1 antibody immunoprecipitation. The co-precipitated 
DNA was analyzed by dot-blotting with a telomere probe to detect telomeric sequences. The 
same blot was hybridized with a probe against centromeric DNA (major satellite) to test the 
ChIP specifity, as TRF1 is bound to telomeres but not centromeres. “No ab” corresponds to the 
same cross-linked DNA incubated with the pre-immune TRF1 antibody serum. “Input” 
corresponds to the chromatin fraction before incubation with the antibody. 
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noticeable in the Trf1
+/+
 p53
 -/-
-Cre sample compared to Trf1-null and input samples 
(Table 4). These results demonstrate in vivo binding of TRF1 to telomeric repeats. 
 
 
 
Our ChIP-seq experiment yielded 11 x 106 uniquely mapped short reads for 
Trf1
+/+
 p53
-/-
-Cre, 32 x 106 for Trf1/ p53-/- -Cre and almost 20 x 106 for input pool 1 
(Table 5). In ChIP-seq experiments, although many mapped reads are dispersed 
throughout the genome, others are found in clusters constituting read-enriched regions, 
which represent the locations of putative binding of the protein of interest. MACS 
(Model-based Analysis of ChIP-seq) software is a computational method that was 
designed to identify read-enriched regions from ChIP-seq data. Significantly read-
enriched peaks were detected using this MACS software, version v1.4 with a P value 
cut-off of 1 x 10
-5
.   
 
 
 
 
 
 
Figure 8: Enrichment of telomere 
sequences bound to TRF1 in ChIP-seq 
experiment. The percentage of 40-bp 
raw reads containing perfect (TTAGGG)5 
or (CCCTAA)5 repeats before alignment 
with mouse genome is shown for the 
different samples. Input pool 1 is a 
combination of equal amounts of input 
DNA from Trf1
+/+ 
p53
-/-
-Cre and Trf1
/ 
p53
-/-
-Cre samples. 
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 Table 4: Total number of reads with (TTAGGG)1,2,3,4,5,6 or (CCCTAA)1,2,3,4,5,6 repeats and % of 
enrichment in samples Trf1
+/+
p53
-/-
-Cre, Trf1
/ 
p53
-/-
-Cre and input pool 1 from ChIP-seq 
experiment before alignment with mouse genome. 
 
To define extra-telomeric TRF1 binding sites, we only retained the peaks that 
were present in Trf1
+/+
 p53
-/-
-Cre sample but not in Trf1-null sample (Trf1
+/+
 p53
-/-
-Cre 
vs Trf1
/
 p53
-/-
-Cre). In the comparisons with the controls, the statistical significance of 
enriched sites is measured by empirical False Discovery Rate (FDR), which is the 
expected proportion of incorrectly identified sites among those found to be significant.  
MACS software calculates the FDR by exchanging the ChIP-seq and control samples. 
In our experiment, a FDR of 10 was applied for this software. 1,165 peaks were found 
in the comparison Trf1
+/+
 p53
-/-
-Cre vs Trf1
/
 p53
-/- 
-Cre. We also did the comparison 
   Trf1+/+p53-/--Cre   Trf1
/ 
p53
-/-
-Cre   Input pool 1  
 Repeats   Nº of reads  %  Nº of reads  %  Nº of reads  % 
 (TTAGGG)
1
  217,345 1.135 185,292 0.665  175,448 0.630  
 (TTAGGG)
2  117,560 0.614  26,550 0.095  6,769 0.024  
 (TTAGGG)
3
  116,975 0.611  26,142 0.094  6,372 0.023  
 (TTAGGG)
4
  115,084 0.601  25,569 0.092  6,091 0.022  
 (TTAGGG)
5
  112,688 0.589  24,930 0.089  5,798 0.021  
 (TTAGGG)
6
  97,075 0.507  21,311 0.076  4,818 0.017  
 (CCCTAA)
1
  206,359 1.078 212,93 0.764  180,765 0.649  
 (CCCTAA)
2
  100,976 0.528  21,473 0.077  4,849 0.017  
 (CCCTAA)
3
  100,426 0.525  21,112 0.076  4,438 0.016  
 (CCCTAA)
4
  98,964 0.517  20,751 0.074  4,278 0.015  
 (CCCTAA)
5
  97,062 0.507 20,327 0.073  4,142 0.015  
 (CCCTAA)
6
  76,033 0.397  15,734 0.056  3,166 0.011  
 (TTAGGG)
1
 + (CCCTAA)
1
   423,704 2.214 398,222 1.429 356,213 1.279 
 (TTAGGG)
2
 + (CCCTAA)
2
  218,536 1.142 48,023 0.172  11,618 0.042  
 (TTAGGG)
3
 + (CCCTAA)
3
  217,401 1.136 47,254 0.170  10,810 0.039  
 (TTAGGG)
4
 + (CCCTAA)
4
  214,048 1.118 46,320 0.166  10,369 0.037  
 (TTAGGG)
5 
+ (CCCTAA)
5
  209,750 1.096 45,257 0.162  9,940 0.036  
 (TTAGGG)
6
 + (CCCTAA)
6
  173,108 0.904  37,045 0.133  7,984 0.029  
 Total nº of reads  19,141,798    26,522,663     27,857,611    
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Trf1
+/+
 p53
-/-
-Cre vs input pool 1, in this case obtaining 1,288 peaks. Out of the 1,165 
peaks from the comparison with the Trf1-null control, 290 were discarded by the 
comparison with the input. Remarkably, all the 875 remaining peaks showed a FDR of 
100%, meaning that TRF1 specific peaks did not have enough statistical support in the 
comparison with Trf1-null sample. 
 
 
 
 
Contrary to what was reported for mouse RAP1 (Martinez et al., 2010) and human 
RAP1, TRF2 and TRF1 (Simonet et al., 2011; Yang et al., 2011), mouse TRF1 peaks 
were not enriched in subtelomeric regions (Fig. 9), as we only found 29 peaks (2.36% 
from the total of peaks) in S regions. If the same analysis was done randomly, the 
expected enrichment in peaks at subtelomeres would be of 2.27%. We observed a slight 
enrichment in chromosomes 4 and 8, of 6% and 5.4% respectively. Besides, most of the 
peaks were not associated with genes, as they mapped in regions at more than 10 kb 
from genes transcription start sites (TSS), with just 13% of the peaks (117 peaks out of 
875) at less than 10 kb from genes TSS (Fig. 10A). From the peaks that mapped inside a 
gene, 90% of them were intronic (Fig. 10B).  
 
Sample 
Raw 
sequenced 
reads 
Size of raw 
sequenced 
reads (bp) 
% of 
alignment 
(PF) 
Uniquely 
mapped reads 
Size of uniquely 
 mapped reads 
(bp) 
Trf1
+/+ 
p53
-/-
-
Cre 
21,493,914 859,756,560 58.36 11,170,552 446,822,080 
Trf1
/
 p53
-/-
-
Cre 
52,426,641 2,097,065,640 91.51 32,673,672 1,306,946,880 
Input Pool 1 37,408,510 1,496,340,400 71.53 19,932,267 797,290,680 
      
Table 5: Summary of ChIP-seq experiment. Overall number of reads obtained and their size. 
% of alignment (PF) is the percentage of filtered reads that were uniquely aligned to the 
reference. The read length is 40 bp. 
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Figure 9: Percentage of peaks 
from Trf1
+/+ 
p53
-/-
-Cre vs Trf1
/ 
p53
-/-
-Cre comparison that  are 
located in non subtelomeric and 
subtelomeric regions (-3 Mbp 
from telomeres). Note that there 
is no enrichment in peaks in 
subtelomeres comparing with the 
random average of enrichment in 
the rest of the genome. The 
chromosomes with higher 
percentage of peaks in S regions 
are 4 and 8.  
 
Figure 10: Distribution of TRF1 peaks in the Trf1
+/+ 
p53
-/-
-Cre vs Trf1
/ 
p53
-/-
-Cre 
comparison. (A) Distance from genes transcription start sites (TSS). Note that most of the 
peaks are 10 kbp from the genes TSS. (B) Distribution of peaks that mapped inside a gene. 
Note that 88.4% of the peaks are intronic.  
 
 
A B 
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1.2. Overlapping with mouse RAP1 ChIP-seq 
To further analyze whether TRF1 binding to chromatin is restricted to telomeres 
in mice, we compared our TRF1 ChIP-seq data with that previously published by us for 
RAP1 (Martinez et al., 2010) and sought peaks that overlapped in both experiments. 
Just a few TRF1 regions (14 sites, 1.6% of the 875 peaks from the comparison Trf1
+/+ 
p53
-/-
-Cre vs Trf1
/
 p53
-/-
-Cre) were found to overlap with RAP1 binding sites and only 
five of them contained telomeric (TTAGGG)n2 tracks (Table 6). While dozens of 
peaks associated with ITSs were found in RAP1 ChIP-seq, in TRF1 ChIP-seq we only 
detected a few peaks in ITSs and with no statitistical significance. In this comparison, 
we also noticed that peaks obtained in TRF1 ChIP-seq were much longer than RAP1 
peaks (RAP1 peaks had an average width of 75 bp, while TRF1 peaks were 576 bp long 
on average). This distribution in broad peaks suggests that peaks obtained in this 
experiment were peaks associated with background instead of peaks showing real 
binding of TRF1. Lastly, RAP1 ChIP-seq showed a much higher number of RAP1 
binding peaks, 30,000 peaks, compared to the 1,165 peaks from TRF1 ChIP-seq 
experiment. 
 
Table 6: Peaks that overlap with RAP1 ChIP-seq in the Trf1
+/+
 p53
-/-
-Cre vs Trf1
/ 
p53
-/- 
-
Cre comparison and that contain tracks with (TTAGGG)n2 repeats 
 
 
1.3. Chip-seq validation by qRT-PCR 
Chr 
RAP1 peak 
number 
Start End 
TRF1 
peak 
number 
Start End 
FDR 
(%) 
2 4 28,040,118 28,040,149 603 28,039,717 28,040,535 100 
2 1 57,482,074 57,482,124 620 57,481,892 57,482,277 100 
6 2027 4,873,918 4,873,946 874 4,873,501 4,874,305 100 
8 2 73,957,000 73,957,029 980 73,956,797 73,957,467 100 
9 7 95,326,334 95,326,363 1073 95,326,167 95,326,779 100 
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Even though none of the TRF1 peaks obtained by ChiP-seq passed the statistical 
significance threshold, we decided to further study those TRF1 peaks in ITSs that 
overlapped with the RAP1 ChIP-seq peaks to be certain that TRF1 does not show 
binding outside of telomeres. We tested the five peaks associated with TTAGGG 
repeats that overlapped with RAP1 (peaks 603, 620, 874, 980 and 1073) (Table 6). In 
addition, we also selected for validation peaks in the subtelomeric regions of 
chromosome 4 and 8, which were the chromosomes that showed a slight enrichment in 
peaks in the S regions (peaks 804, 805 806, 807, 1014, 1015 and 1016) (Table 7). 
 
Table 7: Peaks from subtelomeres of chromosomes 4 and 8, which are the 
chromosomes that showed higher enrichment of peaks in S regions in the comparison 
Trf1
+/+
 p53
-/-
-Cre vs Trf1
/ 
p53
-/- 
-Cre. 
 
To study TRF1 binding to these peaks, we carried out independent ChIP 
experiments with our anti-TRF1 antibody in two MEF lines per genotype; Trf1
+/+ 
p53
-/-
-
Cre MEFs and Trf1
/
 p53
-/-
-Cre MEFs deficient for Trf1 as negative control for peak 
specificity, followed by qPCR analysis with primers for the extra-telomeric regions 
mentioned above (see primer sequences in Experimental Procedures, Table 2). We 
failed to detect TRF1 binding to the indicated ITSs (Fig. 11, left panel) or to 
subtelomeric regions (Fig. 11, right panel), thus confirming that the peaks obtained in 
the ChIP-seq were false positives in agreement with the FDR indicator. Taking all these 
results together, we conclude that mouse TRF1 does not bind to chromosomal regions 
other than telomeres, at least in wild-type MEFs. 
Chr Peak number Start End FDR (%) 
4 804 153,217,553 153,218,190 100 
4 805 154,765,741 154,766,224 100 
4 806 155,161,073 155,161,670 100 
4 807 155,334,959 155,335,528 100 
8 1014 128,849,051 128,849,629 100 
8 1015 129,108,238 129,108,707 100 
8 1016 129,423,259 129,423,839 100 
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Figure 11: Validation of TRF1-binding peaks by ChIP with anti-TRF1 antibody followed 
by qPCR. The peak ranks of the regions tested are indicated on the x axis. Validation of peaks 
that overlapped with RAP1 ChIP-seq and contain (TTAGGG)n2 repeats (Left panel). 
Validation of peaks from subtelomeric regions of chromosomes 4 and 8 (Right panel). The 
results were normalized to the input and relativized to wild-type levels. No decrease in TRF1 
binding was detected in Trf1-null MEFs. n= number of independent MEFs analyzed. Error bars: 
s.e.m. Statistical analysis: Two sided Student’s t-test.  
 
1.4. Identification of TRF1 binding sites upon telomere shortening by ChIP-sequencing 
Interestingly, in yeast telomeric alterations can lead to delocalization from 
telomeres of Rap1-associated heterochromatin factors that are able to operate at 
interstitial genomic sites (Maillet et al., 1996; Marcand et al., 1996). It is also known 
that gradual reduction in the telomere length associated with aging is linked to global 
deregulation of the transcriptome and loss of maintenance of epigenetic silencing 
mechanisms (Schoeftner et al., 2009). Knowing that in normal conditions TRF1 does 
not bind outside telomeres, we hypothesized that upon telomere attrition TRF1 could 
delocalize from telomeres to other regions of the genome, having additional functions 
independent from telomere biology and contributing to the gene expression changes 
associated with aging. To address this, we performed a second ChIP-seq experiment in 
MEFs deficient for Terc, the gene that codifies the telomerase RNA component, for 
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successive mouse generations (Blasco et al. 1997). Samples used were Trf1
+/+
 MEFs 
Terc
+/+ 
(wild-type) and Terc
-/- 
of the first (Terc
-/- 
G1) and third (Terc
-/-
 G3) generations, 
which display progressively shorter telomeres, senescence and chromosomal aberrations 
like end-to-end fusions in advanced generations.  
Again, we first confirmed the enrichment in telomeric repeats before sequence 
alignment with mouse genome in wild-type, Terc
-/-
 G1 and Terc
-/- 
G3 MEFs compared 
to their corresponding input DNA (input pool 2). In agreement with shorter telomeres 
owing to telomerase deficiency, Terc
-/-
 G1 and G3 samples showed gradual decrease in 
the percentage of reads containing 5 perfect telomeric repeats (Fig. 12). A similar 
enrichment was seen for 2, 3, 4 and 6 repeats of the TTAGGG or CCCTAA sequences 
(Table 8). 
 
 
 
This ChIP-seq experiment yielded 14 x 106 uniquely mapped short reads for 
wild-type, 16 x 106  for Terc-/- G1, 15 x 106 for Terc-/- G3 and 21 x 106 for input pool 
2 (Table 9). Peak detection and statistical analysis was done as described above. We 
compared Terc
-/-
 G3 vs wild-type, Terc
-/- 
G1 vs wild-type and Terc
-/-
 G3 vs Terc
-/-
 G1, 
so as to obtain new TRF1 binding sites to the genome while telomeres get shorter. We 
obtained 2,179 peaks in the comparison Terc
-/-
 G3 vs wild-type, 2,207 peaks in the 
comparison Terc
-/-
 G1 vs wild-type and 2,524 peaks in the comparison Terc
-/-
 G3 vs 
Terc
-/-
 G1. However, none of these peaks were of statistical significance and were 
discarded from the analysis. Once again, we did not see any enrichment in S regions in 
Figure 12:  Enrichment of telomere 
sequences bound to TRF1 in ChIP-
seq experiment. The percentage of 
42-bp raw reads before alignment with 
mouse genome containing perfect 
(TTAGGG)5 or (CCCTAA)5 repeats is 
shown for the different samples. Input 
pool 2 is a combination of input DNA 
from wild-type, Terc
-/-
 G1 and Terc
-/-
 
G3 samples. 
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the comparison Terc
-/- 
G3 vs wild-type (1.93% compared to 2.27% of the random 
average) (Fig. 13), suggesting that telomeric shortening and the consequent decreased 
binding of TRF1 to telomeres does not induce TRF1 interaction with other regions of 
the genome. 
 
 
 
 
 
 
 
   wild-type   Terc-/- G1   Terc-/- G3   Input pool 2  
 Repeats  nº of reads  % nº of reads  % nº of reads  % nº of reads  % 
 (TTAGGG)
1
  951,647   3.843  331,362  1.271  296,587  1.147  197,186   0.680  
 (TTAGGG)
2  809,239   3.268  169,543  0.650  143,595  0.556  7,259   0.025  
 (TTAGGG)
3
  806,879   3.258  168,810  0.647  142,801  0.552  6,849   0.024  
 (TTAGGG)
4
  787,802   3.181  166,154  0.637  140,420  0.543  6,607   0.023  
 (TTAGGG)
5
  767,623   3.100  161,835  0.621  136,804  0.529  6,377   0.022  
 (TTAGGG)
6
  742,038   2.996  154,517  0.592  132,819  0.514  6,161   0.021  
 (CCCTAA)
1
  540,729   2.184  242,641  0.930  231,604  0.896  196,350  0.678  
 (CCCTAA)
2
  398,057   1.607  81,759  0.313  75,774  0.293  4,066  0.014  
 (CCCTAA)
3
  397,172   1.604  81,389  0.312  75,280  0.291  3,717  0.013  
 (CCCTAA)
4
  389,551   1.573  80,366  0.308  74,212  0.287  3,576  0.012  
 (CCCTAA)
5
  382,186   1.543   78,819  0.302  72,793  0.282   3,469  0.012  
 (CCCTAA)
6
  373,401   1.508  75,939  0.291  71,232  0.276  3,372  0.012  
 (TTAGGG)
1
 + (CCCTAA)
1
   1,492,376   6.026  574,003   2.201  528,191  2.044  393,536   1.358  
 (TTAGGG)
2
 + (CCCTAA)
2
  1,207,296   4.875  251,302   0.964  219,369  0.849  11,325   0.039  
 (TTAGGG)
3
 + (CCCTAA)
3
  1,204,051   4.862  250,199   0.959  218,081  0.844  10,566   0.036  
 (TTAGGG)
4
 + (CCCTAA)
4
  1,177,353   4.754  246,520   0.945  214,632  0.830  10,183   0.035  
 (TTAGGG)
5 
+ (CCCTAA)
5
  1,149,809   4.643  240,654   0.923  209,597  0.811  9,846   0.034  
 (TTAGGG)
6
 + (CCCTAA)
6
  1,115,439   4.504  230,456   0.884  204,051  0.789  9,533   0.033  
 Total nº of reads  24,763,644   26,079,916   25,846,525   28,980,120   
Table 8: Total number of reads with (TTAGGG)1,2,3,4,5,6 or (CCCTAA)1,2,3,4,5,6 repeats in 
wild-type,  Terc
-/- 
G1, Terc
-/- 
G3 and input pool 2 samples from the second ChIP-seq 
experiment before alignment with mouse genome.  
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Sample 
Raw 
sequenced 
reads 
Size of raw 
sequenced reads 
(bp) 
% of 
alignment 
(PF) 
Uniquely 
mapped reads 
Size of uniquely 
mapped reads 
(bp) 
Wildtype 29,609,663 1,243,605,846 58.54 14,498,028 608,917,176 
Terc
-/-
 G1 31,473,982 1,321,907,244 63.43 16,542,830 694,798,860 
Terc
-/-
 G3 30,741,283 1,291,133,886 59.88 15,476,230 650,001,660 
Input Pool 2 35,229,238 1,479,627,996 73.78 21,381,218 898,011,156 
Table 9: Summary of second ChIP-seq experiment. Overall number of reads 
obtained and their size. % of alignment (PF) is the percentage of filtered reads that 
were uniquely aligned to the reference. In this second experiment,the read length is 
42 bp. 
Figure 13: Percentage of 
peaks from the Terc
-/- 
G3 vs 
wild-type comparison that  
are located in non 
subtelomeric and 
subtelomeric regions (-3 Mbp 
from telomeres). There is no 
enrichment in peaks in 
subtelomeres comparing with 
the random average of 
enrichment in any other region 
in the genome. 
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2. Dissecting the reprogramming process: shelterins and telomerase in iPS 
cell generation 
Differentiated cells can be reprogrammed to a more pluripotent state by a process 
named nuclear reprogramming. The most recent approach for nuclear reprogramming 
consists in the overexpression of a combination of four core transcription factors 
(Oct3/4, Sox2, Klf4 and c-Myc), leading to the so-called induced pluripotent stem (iPS) 
cells, which closely resemble ES cells (Takahashi and Yamanaka, 2006). It is known 
that during this process telomeres are also reprogrammed, resulting in a telomere 
elongation that is mainly telomerase-dependent (Marion et al., 2009b). The feasibility of 
clinical applications of iPS cells is dependent on the quality of these cells and the 
maintenance of their genomic stability, in order to avoid the danger of transformation. 
In this sense, ensuring telomere protection and capping during the formation and 
maintenance of iPS cells is crucial. In this thesis we set forth to study the role and 
dynamics of different proteins associated with telomere biology during nuclear 
reprogramming. 
 
 2. 1. TRF1 is essential for reprogramming 
As we explained before, TRF1 has fundamental roles in telomere protection and 
replication, since its deletion in MEFs causes telomere fragility, chromosomal 
aberrations,  replication fork stalling and a DDR leading to severe cell cycle arrest and 
senescence (Martinez et al., 2009; Sfeir et al., 2009). Moreover, TRF1 has been 
established as a stem cell marker that is significantly upregulated in ES and iPS cells 
compared to the starting cell populations both in humans and mice (Boue et al., 2010; 
Ginis et al., 2004; Hosseinpour et al., 2013; Schneider et al., 2013). Based on this, we 
decided to study the effect of Trf1 abrogation during the reprogramming process. To 
this end, we reprogrammed MEFs knockout for Trf1 in order to determine if TRF1 was 
essential for reprogramming. A scheme of the experiment is shown in Fig. 14.  
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As we have already explained, p53 abrogation rescues proliferative defects 
associated with Trf1 deficiency (Martinez et al., 2009). On top of that, p53 has been 
described as a barrier for reprogramming. In this way, its abrogation during 
reprogramming increases the efficiency of this process, by facilitating the 
reprogramming of cells with severe DNA damage (Hong et al., 2009; Kawamura et al., 
2009; Li et al., 2009; Marion et al., 2009a; Utikal et al., 2009). Hence, we 
reprogrammed MEFs simultaneously deficient for Trf1 and p53. Prior to 
reprogramming, Trf1
+/+
 p53
-/-
 and Trf1
lox/lox
 p53
-/- 
MEFs were infected with pBabe- 
puro-Cre and selected with puromycin for one week. TRF1 decrease was confirmed by 
Western blot (Fig. 15). As addition of c-Myc in the reprogramming cocktail was 
previously shown to be dispensable for the obtaining of iPS cells, for telomerase 
activation and for the elongation of telomeres associated with the reprogramming 
process (Wernig et al. 2007; Marion 2009a), we reprogrammed 200,000 cells per MEF 
line by four consecutive infections (Day 0 and 1) of the three retroviral Yamanaka 
factors Oct3/4, Sox2 and Klf4. In parallel, we also infected cells with retroviral pBabe-
GFP plasmid and checked infection efficiency by flow cytometry so as to calculate the 
reprogramming efficiency.  
 
Figure 14: Scheme of the reprogramming approach. 
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 After two weeks, we failed to obtain any iPS cell colonies in the majority of the 
Trf1
∆/∆
 p53
-/-
-Cre cultures. In some of the wells, we obtained a few colonies with the 
same timing of Trf1
+/+
 p53
-/-
-Cre. The number of alkaline phosphatase positive 
colonies, which are the true pluripotent colonies, was scored after two weeks to 
Figure 16: Reprogramming of Trf1 ablated MEFs. (A) Reprogramming plates stained with 
alkaline phosphatase (AP). The number of parental MEFs used is indicated. (B) Relative 
reprogramming efficiencies of the indicated cells. n= number of independent MEF lines. Error 
bars: s.e.m. Statistical analysis: Two sided Student’s t-test. (C) Analysis of Trf1 excision in 
iPS colonies obtained from Trf1
/
 p53
-/-
-Cre MEFs by PCR. Note that all the clones keep the 
Trf1 locus.  
Figure 15: Western blot for TRF1 protein. 
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calculate reprogramming efficiency (Fig. 16A). A decreased of three times in the 
reprogramming efficiency was seen in Trf1
/
 p53
-/-
-Cre MEFs compared to Trf1
+/+
 p53
-
/-
-Cre MEFs (Fig. 16B). Colonies of both genotypes were picked in feeders and 
amplified to check the excision. All the iPS colonies obtained in the case of Trf1
/
 p53
-
/-
-Cre cultures retained the Trf1
lox 
allele, indicating that those colonies were wild-type 
escapers of the infection with Cre recombinase (Fig. 16C). Therefore, we conclude that 
Trf1 deficiency completely blocks reprogramming, even in the absence of p53. 
 Some of the key events associated with reprogramming are the upregulation of 
pluripotency markers. The surface antigen Stage-Specific Embryonic Antigen 1 (SSEA-
1) is expressed in ES cells (Cui et al. 2004) and is upregulated at early time-points 
during reprogramming, whereas the increase in the expression of endogenous 
pluripotency genes Nanog and Oct3/4 is a late step during reprogramming, being 
considered markers of fully reprogrammed cells (Brambrink et al., 2008; Stadtfeld et al., 
2008a). We checked these pluripotency markers at different time-points during 
reprogramming by flow cytometry (SSEA-1) or by qRT-PCR (Nanog and Oct3/4). Trf1 
deficiency prevented the appearance of SSEA-1 positive clones, while wild-type control 
reprogramming cells started expressing SSEA-1 by day 5 of reprogramming (Fig. 17A). 
As expected, we detected increased expression of Nanog and Oct3/4 before the 
appearance of the first iPS clones (11-14 days post-infection), while Trf1
/
 p53
-/-
-Cre 
did not show this increase, concordantly with reduced Trf1 mRNA levels. We detected a 
slight increase in these markers in the Trf1
/ p53
-/-
-Cre MEFs concomitant with an 
increase in Trf1 expression from days 9 to 14, probably corresponding to MEFs that 
escaped the excision (Fig. 17B). 
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2.2. Trf1 knockdown MEFs reprogram with lower efficiency 
 In view that Trf1 deficiency completely blocks reprogramming, even in the 
absence of p53, we set to confirm this essential role of TRF1 in reprogramming by 
knocking down Trf1 expression during the reprogramming process. To this end, p53
-/-
 
MEFs were reprogrammed using a cocktail of retroviral vectors expressing the three 
reprogramming factors (Oct3/4, Klf4 and Sox2) and a lentiviral vector expressing either 
Trf1 shRNA or a scramble shRNA as a control. As expected, reduced expression of Trf1 
during reprogramming strongly decreased the reprogramming capacity of the cells 
(Fig.18A-B). To confirm that the colonies obtained in the shTrf1 treatment were not 
escapers, we picked colonies, amplified them and analyzed TRF1 levels by Western blot 
(Fig. 18C-D). We observed a decreased in TRF1 protein levels in the two colonies with 
the shTrf1 compared to those with the scramble, concluding that cells with low levels of 
TRF1 are capable to reprogram, but with a lower efficiency than wild-type cells. 
Figure 17:  Trf1-null MEFs do not express SSEA-1, Nanog and Oct3/4 pluripotency 
markers upon infection with 3F. (A) Kinetics of expression of SSEA-1 pluripotency marker 
during reprogramming, as measured by flow cytometry. Non-reprogrammed MEFs are shown as 
negative control.  n= number of independent MEF lines. Error bars: s.e.m. (B) mRNA levels of 
Oct3/4, Nanog and Trf1 at days 9, 11 and 14 of reprogramming, before appearance of iPS 
colonies. The mRNA levels are measured by qRT-PCR relative to Gapdh mRNA levels. n=  
number of independent MEF lines. Error bars: s.e.m. Statistical analysis: two sided Student’s t-
test. 
A B 
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 As Trf1 deficiency results in activation of a DDR at telomeres, we checked for 
DNA damage foci by co-staining of γH2AX and TRF1. In line with this, we found an 
increased intensity of γH2AX per nucleus in cells with reduced levels of TRF1 at day 8 
post-infection (Fig. 19A), suggesting that increased DNA damage may be responsible 
for the deficient reprogramming capacity of these cells. We have previously described 
that Trf1 deletion leads to chromosome instability in MEFs, characterized by the 
presence of aberrations like chromosome or chromatid end-to-end fusions and 
A B 
Figure 18: Down-regulation of TRF1 during reprogramming decreases dramatically the 
reprogramming efficiency. (A) Reprogramming plates stained with alkaline phosphatase. (B) 
Relative reprogramming efficiency of the indicated cells. Note that shTrf1-transduced MEF line 
shows decreased reprogramming capacity. n= number of independent MEF lines. (C) Western 
blot for TRF1 in nuclear extracts from iPS colonies obtained from MEFs infected with scramble 
or shTrf1. Two iPS clones per treatment were picked. MEFs were included as a control. (D) 
Quantification of the Western blot shown in C. Values are in arbitrary units (a.u.). 
C D 
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multitelomeric signals (MTS), which reflect telomere uncapping and fragility, 
respectively. We observed a significant increase in MTS at day 17 post-infection (p.i.), 
but not at an earlier time-point (day 10 p.i.), in cells with Trf1 downregulation when 
compared to cells with normal levels of TRF1 (Fig. 19B), suggesting that accumulation 
of MTS may be associated with the number of cell doublings to form an iPS cell colony. 
 
 
 
 
 
 
 
 
Figure 19: Downregulation of Trf1 during reprogramming induces DNA damage 
and telomere aberrations. (A) Quantification of TRF1 and γH2AX 
immunofluorescence after infection with the indicated viral cocktails (day 8 p.i). 
n=number of cells analyzed. Error bars: s.e.m. Statistical analysis: two sided Student’s 
t-test. (B) Frequency of multitelomeric signals in cells 10 days (no presence of iPS 
colonies) or 17 days (presence of iPS cells) after infection with the indicated viral 
cocktails. n= number of metaphases analyzed. Error bars: s.e.m. Statistical analysis: 
two sided Student’s  t-test. 
A 
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2.3. Induction of apoptosis, chromosomal aberrations and DDR activation in Trf1-
deficient iPS cells 
Next, we wondered whether TRF1 could be essential not only during the 
acquisition of pluripotency, but also for the maintenance of the pluripotent state. To this 
end, we generated Trf1-null iPS cells using primary MEFs carrying the aforementioned 
conditional loxP-flanked Trf1 allele and a Cre recombinase allele ubiquitously 
expressed under the control of the locus encoding the large subunit of RNA polymerase 
II (RERTn) (Guerra et al., 2003). This Cre recombinase is merged to the binding domain 
of the modified estrogen receptor (ERT2), being translocated to the nucleus upon 
treatment with the synthetic steroid 4-hydroxytamoxifen (4-OHT). After 
reprogramming of Trf1
+/+
RERTn
+/ERT
 and Trf1
lox/lox
RERTn
+/ERT
  MEFs by infections 
with the three OSK factors (as previously described), the resultant iPS cells were 
picked, replated and treated with 0.2 M 4-OHT to obtain Trf1 wild-type and Trf1-null 
iPS cells, respectively. IPS medium with 4-OHT was changed every day (Fig. 20).  
 
 
 
The phenotype of Trf1 deletion in iPS cells was fast and severe, since practically 
all the Trf1-null iPS colonies were death by day 6 of 4-OHT treatment (Fig. 21A). We 
confirmed Trf1 abrogation in Trf1
/
RERTn
+/ERTOHT
 iPS cells by qRT-PCR at day 3 and 
6 of 4-OHT treatment (Fig. 21B). 
 
Figure 20: Scheme of the approach for the obtaining of conditional Trf1 knockout iPS 
cells. 
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Thereafter, we wanted to know whether this Trf1-deletion induced cell death in 
iPS cells was mediated by apoptosis. To this end, we checked Annexin-V staining by 
flow cytometry at day 3 and 6 of 4-OHT treatment. Even if the initial levels were 
abnormally high in both genotypes, we observed a robust increase in apoptosis in Trf1
/ 
RERTn
+/ERTOHT
 iPS cells compared to the Trf1
+/+ 
RERTn
+/ERTOHT 
iPS cells by day 6 of 
treatment (Fig. 22A-B).  
        
 
 
Figure 21: Conditional Trf1 deletion in iPS cells. (A) Representative bright-field images 
showing the effect of Trf1 abrogation in iPS cells. (B) Trf1 mRNA levels decrease with time of 
4-OHT treatment at day 3 and day 6. Ctrl are control treated cells at day 3 where no difference in 
the Trf1 mRNA levels was detected. n= number of iPS cell clones. Error bars: s.e.m. Statistical 
analysis: Two sided Student’s t-test. 
Figure 22:  Induction of apoptosis in Trf1 knockout iPS cells. (A) Apoptosis was 
determined on control treated iPS cells and iPS cells at day 3 and 6 of 4-OHT treatment. n= 
number of iPS clones analyzed. Error bars: s.e.m. Statistical analysis: Two sided Student’s t-
test. (B) Representative FACS profiles at day 6 of 4-OHT treatment.  
B A 
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To address whether Trf1 deficiency causes telomeric aberrations in iPS cells, we 
performed Q-FISH by hybridization with a telomeric (TTAGGG)3 probe. For this, iPS 
cells were arrested in metaphase by three hours treatment with colcemid, which 
prevents spindle formation during mitosis. As expected, Trf1
/ 
RERTn
+/ERTOHT
 iPS cells 
showed higher levels of multitelomeric signals, sister-chromatid and chromosome end-
to-end fusions at day 3 and 6 after 4-OHT treatment (Fig. 23), suggesting increased 
telomere fragility and telomere uncapping due to Trf1 abrogation. 
 
 
 
                                                          
  
 
 
 
 
 
Figure 23:  Trf1-null iPS cells show chromosomal aberrations. (A) Frequency of 
aberrations in metaphase spreads of the indicated genotypes and conditions. n= number of 
metaphases from a total of two iPS clones per genotype. Error bars: s.e.m. Statistical 
analysis: Two sided Student’s t-test. (B) Representative images of the aberrations. Red 
arrows highlight the indicated aberrations; Yellow: telomeres (TTAGGG)3 probe; Blue: 
Dapi. 
Sister-chromatid 
fusion 
Multitelomeric 
signal 
B 
A 
Chromosomal  
fusion 
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 Finally, we analyzed DDR activation by immunofluorescent co-staining of 
γH2AX and TRF1 in iPS cells at day 3 of 4-OHT treatment. We detected a considerable 
increase in the percentage of γH2AX positive cells (Fig. 24) in Trf1/RERTn+/ERTOHT 
with low levels of TRF1 compared to Trf1
+/+
RERTn
+/ERTOHT 
and Trf1
/
RERTn
+/ERTOHT 
with high levels of TRF1, in agreement with the results from Trf1-null MEFs.  
Together, these findings indicate that TRF1 is essential both for the induction and 
maintenance of pluripotency in iPS cells. 
 
 
 
 
 
 
 
Figure 24: Trf1-null iPS cells show DNA damage. (A) Percentage of γH2AX 
positive cells in non-treated (Ctrl) and 4-OHT treated (Day 3) iPS cells. n= number 
of iPS clones used for the analysis. The total number of cells analyzed per genotype 
is shown. Error bars: s.e.m. Statistical analysis: Two sided Student’s t-test. (B) 
Representative images of TRF1 and γH2AX immunofluorescence co-staining.  
B 
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2.4. Ectopic expression of Trf1 does not affect reprogramming efficiency or replace any 
of the OSK factors during reprogramming 
High TRF1 levels are observed not only in established ES cells but also in 
cultured ICM cells before telomere elongation, probably to assure telomeres protection 
as they are elongated (Varela et al., 2011). As we said before, TRF1 levels dramatically 
increase in iPS cells compared to differentiated cells. It has been previously 
demonstrated by us that this TRF1 increase is uncoupled from telomere elongation, as 
Tpp1
∆/∆
 Cre-shp53 iPS cells, which show impaired telomere elongation (Tejera et al., 
2010), exhibit TRF1 levels similar to those of wild-type iPS cells, implying a role of 
TRF1 protein apart from telomere maintenance (Schneider et al., 2013). Besides, it has 
been reported that the ectopic expression of factors that protect telomeres, such as 
Zscan4, can increase efficiency of reprogramming (Jiang et al. 2013). Once we 
demonstrated that Trf1 is essential for reprogramming and maintenance of iPS cells, we 
wondered whether ectopic expression of this protein could modulate reprogramming 
efficiency. On top of that, we also wanted to know if Trf1 could replace any of the three 
Yamanaka factors (Oct3/4, Sox2, Klf4) in the reprogramming cocktail. To address this, 
we carried out a reprogramming assay with MEFs overexpressing Trf1 (Fig. 25). 
 
 
To this end, we cloned mouse Trf1 cDNA in a retroviral pBabe-puro-Empty 
Vector (EV) backbone with puromycin selection. Our approach was to infect wild-type 
MEFs with the three Yamanaka factors (OSK, 3F) in combination with pBabe-puro-
Figure 25: Scheme of the approach for reprogramming of MEFs overexpressing Trf1 
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Trf1 or the corresponding pBabe-puro-EV mock control and selected them with 
puromycin. Besides, we also infected MEFs with two Yamanaka factors (OK, OS and 
SK) combined with either pBabe-puro-Trf1 or pBabe-puro-EV. We began by testing our 
plasmid by Western blot for TRF1 at day 6 of reprogramming, confirming TRF1 
overexpression (Fig. 26A). In the case of reprogramming with 3F, iPS colonies 
appeared at the same time in both control and Trf1 overexpressing MEFs at day 14 post-
infection (Fig. 26B). Trf1 overexpression did not affect the reprogramming efficiency 
either, as it is shown in the alkaline phosphatase staining from day 16 (Fig. 26C-D). In 
contrast, we did not obtain any colonies in the 2F reprogrammings by day 35 (Fig. 
26C), indicating that Trf1 is not able to replace any of the OSK factors in the cocktail of 
reprogramming.  
 
 
2.5. Overexpression of Tert and/or Tpp1 does not lead to differences in reprogramming 
efficiency  
Figure 26: Reprogramming of MEFs overexpressing Trf1. (A) Western blot showing 
increased levels of TRF1 in MEFs infected with pBabe-puro-Trf1. (B) Bright-field images at 
day 6 and 14 of reprogramming. (C) Alkaline phosphatase staining of MEFs infected with 
3F (OSK) at day 16 and with 2F (OS, SK and OK) at day 35 of rep ogramming. Note that no 
iPS colonies appeared in the case of 2F reprogramming. (D) Relative reprogramming 
efficiency of MEFs infected with pBabe-puro-Trf1 compared to the control infected with 
pBabe-puro-EV. n= number of independent MEF lines. Error bars= s.e.m. 
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As we mentioned before, iPS cell formation is associated with an increase in 
telomerase activity (Takahashi and Yamanaka, 2006), which takes place late in the 
reprogramming process (Stadtfeld et al., 2008a). Consequently, telomeres elongate 
during reprogramming, specially post-reprogramming (Marion et al., 2009b) and this 
elongation has been described to be crucial for the proliferative capacity, stability and 
differentiation potential of the resultant iPS cells. On top of that, ectopic expression of 
the catalytic subunit of telomerase Tert confers growth advantages in MEFs. This effect 
is independent of telomere elongation and seems to be related with a role of Tert 
through inhibition of the TGF- pathway (Geserick et al., 2006). Besides, mice Tert-/- 
tail-tip fibroblasts (TTFs) have been shown to reprogram with lower efficiency, also 
independent of their telomere length (Kinoshita et al., 2014). This evidence suggests 
that TERT could have extra-telomeric functions that positively modulate 
reprogramming capacity. 
Factors that can regulate telomerase expression, recruitment or activity are also 
expected to play a significant part in iPS cell formation. TPP1 interaction with 
telomerase has been described to be necessary for high processivity of telomerase 
enzyme (Zaug et al., 2010). Moreover, TPP1 is essential for the telomere elongation that 
takes place during reprogramming by facilitating the recruitment of telomerase (Tejera 
et al., 2010).  
Based on this, we wanted to know if Tert overexpression, alone or in combination 
with Tpp1 overexpression during reprogramming could influence reprogramming 
efficiency. To test this, we cloned mouse Tert and Tpp1 cDNAs in a lentiviral vector 
and overexpressed them during reprogramming. Since c-MYC is a well characterized 
regulator of Tert (Flores et al., 2006), we carried out our reprogramming assay both in 
the presence and absence of c-Myc in the reprogramming cocktail. Wild-type MEFs 
from low passages were infected with 3 (OSK) and 4 (OSKM) reprogramming factors 
in combination with pLVX-EV, pLVX-Tert, pLVX-Tpp1 or pLVX-Tert + pLVX-Tpp1. 
Reprogramming efficiency was tested by alkaline phosphatase staining at day 9 (4F) or 
day 11 (3F) post-infection (Fig. 27). As expected, MEFs infected with 4F 
reprogrammed much faster and with higher efficiency than with 3F, since c-MYC 
enhances reprogramming efficiency although it is dispensable for the obtaining of iPS 
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cells (Wernig et al., 2008). However, no differences in the reprogramming efficiency or 
colony appearance timing were observed in any of the conditions tested, concluding that 
Tpp1 or Tert overexpression does not affect reprogramming efficiency. 
 
 
 
 
We checked the increase in both Tert and Tpp1 mRNA levels by qRT-PCR at day 
4 of reprogramming relative to day 0 (Fig. 28). In the case of Tert, we showed a robust 
increase in pLVX-Tert and pLVX-Tert + pLVX-Tpp1 infected MEFs compared to 
control MEFs with EV in 3F reprogramming. Surprisingly, Tert overexpression was 
milder in 4F reprogramming (Fig. 28, left). Tpp1 also showed a higher upregulation in 
the 3F approach compared to 4F (Fig 28, right). These differences between 3F and 4F 
could be due to the silencing of the lentivirus, one of the late events of the 
reprogramming process (Stadtfeld et al., 2008a), associated with the faster 
reprogramming of MEFs infected with 4F. 
 
Figure 27: Reprogramming of MEFs overexpressing Tert and/or Tpp1. Alkaline 
phosphatase staining at day 9 (4F) and day 11 (3F) post-infection. Note that 
reprogramming efficiency is much higher in MEFs reprogrammed with 4F. 
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2.6. Shelterins and telomerase dynamics during reprogramming 
A lot of effort has been made in the field of reprogramming trying to unveil the 
steps leading to the formation of iPS cells. It is clear that there is a connection between 
telomerase and reprogramming, but little is known about the dynamics of shelterins 
during this process. At least two of the proteins of the shelterin complex, TRF1 and 
TRF2, have been described to be upregulated in ES and iPS cells, being considered as 
stem cell markers (Boue et al., 2010; Ginis et al., 2004; Hosseinpour et al., 2013; 
Schneider et al., 2013). Besides, we recently showed that Trf1 upregulation takes place 
early in reprogramming (Schneider, 2013). However, nothing is known about the rest of 
the shelterins.  
In the last years, several publications have been released dissecting the 
pluripotency roadmap by the use of high-throughput techniques (Buganim et al., 2012; 
Hansson et al., 2012; Mah et al., 2011; O'Malley et al., 2013; Polo et al., 2012; Soufi et 
al., 2012). Polo and collegues examined defined intermediate cell populations poised to 
becoming iPSCs by genome-wide analyses. They reported that induced pluripotency 
elicits two transcriptional waves, which are driven by c-MYC/KLF4 (first wave) and 
OCT3/4/SOX2/KLF4 (second wave) (Polo et al., 2012). Using these microarray data, 
we checked shelterins and telomerase dynamics during the reprogramming process. As 
it is seen in Fig. 29, Trf1 and Tin2 showed an obvious increase, more pronounced at the 
beginning and at the end of reprogramming. Trf2 and Rap1 displayed a similar pattern 
Figure 28: Tert and Tpp1 mRNA levels at day 4 of reprogramming relative to 
day 0. n= 3 independent MEF lines. Error bars= s.e.m. 
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of expression, as they decreased during the process of reprogramming. Surprisingly, no 
increase was detected in the case of Tert expression. The same happened with Tpp1. 
Lastly, in the case of Pot1a, a mild increase was shown. 
 
 
 
 
In order to validate these results, we analyzed the expression of these genes during 
reprogramming by qRT-PCR. We took advantage of a “reprogrammable” transgenic 
mouse strain (inducible four factors, i4F) from the laboratory of Manuel Serrano, which 
is a useful tool that allows us to reprogram MEFs faster and more homogeneously 
(Abad et al., 2013). This reprogramming system consists in MEFs carrying the 
doxycycline-inducible transcriptional transactivator (rtTa) and a single copy of a 
lentiviral polycistronic cassette encoding the four murine reprogramming factors 
(Oct3/4, Sox2, Klf4 and c-Myc) under the control of the tetO element. Upon doxycycline 
addition, iPS colonies appear after one week. A scheme of the experiment is depicted in 
Fig. 30. 
 
Figure 29: Expression analysis of the indicated genes at day 0 (MEF), 3, 6, 9 and 12 of 
reprogramming and in established iPS cells. Cells were sorted based on THY, SSEA-1 and 
Oct-GFP
 
markers, selecting for cells undergoing successful reprogramming at day 3, 6 and 9 
(THY
-
/ SSEA-1
+
) and day 12 (THY
-
/ SSEA-1
+
/ Oct-GFP
+
) (Adapted from Polo et al. 2012).  
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We added doxycycline one day after MEF seeding (day 0) and analyzed shelterins 
and telomerase components expression by qRT-PCR every two days (day 0, 2, 4, 6, 8, 
10 and 12) and in established iPS cells obtained from these MEFs (Fig. 31). Nanog 
expression was checked to confirm the dynamics of the reprogramming. In regards to 
telomerase components, we observed an increase in Tert expression at the beginning of 
reprogramming. By contrast, Terc progressively increases during the reprogramming, 
reaching over an 8-fold upregulation in iPS cells compared to MEFs. Regarding 
shelterins, we noticed a slight increase at the beginning of reprogramming (day 0 to day 
4) in all the shelterins, although most of them came back to the initial levels in 
established iPS cells, except Trf1 and Pot1a. In the case of Trf1, we observed an 
increase of around four times in iPS cells compared to MEFs. We have previously 
described that OCT3/4 is able to directly bind to Trf1 promoter regulating its expression 
in pluripotent cells, both ES and iPS cells (Schneider et al., 2013). Further studies are 
needed to elucidate whether the expression of the rest of the shelterins is also regulated 
by reprogramming factors. 
 
 
Figure 30: Scheme of the reprogramming approach with the reprogrammable i4F MEFs 
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Figure 31:  Slight 
increase in shelterins 
mRNA levels at the 
beginning of 
reprogramming.  
mRNA levels relative to 
day 0 were represented 
for days 0, 2, 4, 6, 8, 10 
and 12 of reprogramming 
(days on doxycycline 
treatment) and in 
established iPS cells 
obtained from these 
MEFs.  n= 5 i4F MEF 
lines (2 independent 
experiments). Error bars 
= s.e.m. 
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1. Identification of putative extra-telomeric binding of TRF1 
Restricted binding of TRF1 to telomeres in normal conditions and upon telomere 
shortening in mice 
The aim of this study was to establish the genome-wide DNA binding patterns of 
the telomeric dsDNA binding protein TRF1 in MEFs and find out whether telomere 
shortening could induce delocalization of TRF1 from telomeres and binding to other 
regions in the genome. When we analyzed TRF1 specific binding sites by ChIP 
sequencing, however, none of the peaks obtained had enough statistical significance and 
were statistically considered false positives. In agreement with this, we could not 
validate the TRF1 peaks by ChIP-qRT-PCR, further indicating that mouse TRF1 
binding to chromatin is restricted to telomeres, at least in MEFs.  
This is in apparent conflict with what was previously observed in a work done in 
humans, where they identified a limited number of extra-telomeric TRF1 binding sites 
that largely comprised ITSs in human tumor cell lines (Simonet et al., 2011). Another 
group also reported binding of TRF1 to an ITS that form a common fragile site, also in 
humans (Bosco and de Lange, 2012). Simonet and colleagues used BJ-HELTRas
mc 
tumor cell line, which are Ras-transformed BJ-HELT fibroblasts (SV40/hTERT-
immortalized human BJ fibroblasts) where TRF2 seems to have a role in oncogenesis 
mediated by extra-telomeric binding (Biroccio et al. 2013). This fact suggests that TRF1 
could also have additional functions in these cells. It is well established that both TRF1 
and TRF2 are overexpressed in several cancers, suggesting that they could carry out 
extra-telomeric functions different from non transformed cells. In the second study from 
Bosco and de Lange, also done in transformed human fibroblasts, they described the 
binding of TRF1 to an especial ITS located in the human chromosome region 2q14 and 
associated with a fragile site, which was originated from a telomere-telomere fusion of 
two ancestral ape chromosomes. We have to take into consideration that not only 
protein binding profiles but also ITSs structure and length differ between humans and 
mice, which may explain the differences in TRF1 binding observed in both species. The 
fact that the human studies were performed in transformed cell lines, while we studied 
TRF1 binding to chromatin in normal primary cells, may also account for the different 
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results, as the specific cellular context could have an effect on TRF1 levels and 
determine  its ability to bind to certain regions. 
It has also been reported that TRF1 binds to ITSs in immortalized Chinese 
hamster cells, where it is involved in the stability of these repeated sequences (Krutilina 
et al., 2001; Krutilina et al., 2003). Unlike mouse cells, however, the Chinese hamster 
cells contain large blocks of cytologically detectable het-ITSs that correspond to 5% of 
their genome, which probably have completely different stabilization and protection 
mechanisms, and this may also explain the differences with our study. 
Finally, we found very few TRF1 peaks associated with ITSs in MEFs when 
compared with an analogous RAP1 ChIP-seq also in MEFs and we could not validate 
them by ChIP-RT-PCR, suggesting that indeed those putative TRF1 peaks may be 
artifacts of the sequencing technique owing to erroneous alignment of telomeres to ITSs 
rather than bona fide TRF1 binding sites. When studying genome-wide DNA binding 
profiles, protein concentration can be critical in the identification of statistically 
significant peaks. In fact, in a ChIP-seq experiment done with anti-TRF2 and anti-RAP1 
antibodies in humans, they demonstrated that TRF2 concentration could considerably 
influence this protein’s binding to ITSs (Yang et al., 2011). Even so, we previously 
published a TRF1 ChIP-seq done in iPS cells, which display high TRF1 levels, showing 
no significant TRF1 binding to putative regulatory regions nor intragenic binding of this 
protein outside telomeric regions (Schneider et al., 2013). 
Given our negative findings with TRF1, it would be interesting to study the 
genome-wide DNA binding profiles for TRF2, which also binds to dsDNA and recruits 
RAP1 to telomeres. In fact, we previously demonstrated that TRF2 binds to TTAGGG-
rich extra-telomeric RAP1 binding sites (Martinez et al., 2010). It is well established 
that TRF1 and TRF2 share the binding domain to DNA but they do not interact and 
bind independently to the DNA. We expected that TRF1 would have similar binding to 
ITSs similar to TRF2. Nevertheless it has been published that these two proteins 
recognize the DNA in a different way, as TRF1 binds slightly more strongly to DNA 
than TRF2 (Hanaoka et al., 2005) and they use different mechanisms to find telomeric 
DNA (Lin et al., 2014). Apart from the slight dissimilarities in binding to DNA, TRF1 
and TRF2 differ in their N-terminal domain, which is acidic in TRF1 and basic in 
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TRF2. This could equally influence the distinct binding and functions of these two 
proteins. 
Telomere shortening is accompanied by a change in the architecture of telomeric 
and subtelomeric chromatin leading to a more “open” chromatin state.  However, this 
loss of telomeric repeats in G2 and G5 Terc
-/-
 MEFs has no effect on TRF1 density at 
telomeres, inferring that no alterations of TRF1 binding to telomeres are associated with 
telomere shortening (Benetti et al., 2007). Besides, it is known that TRF1 protein levels 
are significantly reduced in late generation Terc
-/- 
mice (Franco et al., 2002). These two 
data together with our results suggest that TRF1 expression and degradation are tightly 
regulated in mice and that telomeric shortening induces a decrease in TRF1 levels rather 
than a relocalization of this protein to other regions in the genome. In fact, TRF1 release 
from telomeres induces its ubiquitylation and subsequent degradation via proteosome 
(Chang et al., 2003). Nevertheless, it is known that a fraction of TRF1 can also exist 
free in the nucleus (McKerlie and Zhu, 2011). In humans, CDK1 phosphorylates TRF1 
at T371 (pT371), keeping TRF1 free of telomere chromatin and protected from 
proteasome-mediated protein degradation. This phosphorylation is upregulated during 
mitosis but during interphase, in response to ionizing radiation (IR), phosphorylated 
TRF1 is recruited to sites of DSB and forms damage-induced foci, promoting the repair 
of these IR-induced DSBs by homologous recombination (HR) (McKerlie et al., 2013). 
It would be interesting to clarify if this extra-telomeric function of TRF1 is preserved in 
mice after DNA damage induction. In this way, further studies of the extra-telomeric 
binding of TRF1 and other shelterins in a context of telomere shortening, other 
pathological conditions or DNA damage induction are needed. Besides, a deeper 
knowledge of the structure, function and stability of these ITSs in the different species 
will help us to understand the dissimilar binding of shelterins to these regions. 
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2. Dissecting the reprogramming process: shelterins and telomerase in iPS 
cell generation 
Regarding therapeutic purposes, iPS cells bypass the ethical issues that limit 
application of ES cells, as they avoid the need for blastocyst-derived ES-cells. Besides, 
since they are derived from the patient’s own cells, they are thought to represent a 
renewable and immunologically compatible cell source for cell replacement therapy. In 
this way, iPS cells have the potential to be used in age-related infertility and age-related 
diseases. Moreover, generation of iPS cells from patients provides in vitro models to 
understand the mechanisms involved in the development of diseases, as it is the case of 
iPS obtained from dyskeratosis congenita patients. 
In addition to the applications in regenerative medicine, iPS cells serve as a tool 
for studying developmental processes at earliest embryonic stages. It is known that 
telomere status changes during embryo development and ES cells derivation.  At the 
preimplantation embryo-stage, telomeres are effectively elongated by ALT-like 
mechanism from totipotent zygote to blastocist and then telomerase is used to maintain 
telomere length during ontogenesis in adult stem cells (Liu et al., 2007). Hence, the 
study of telomere remodeling during reprogramming could also help us to understand 
the mechanisms underlying telomerase and shelterin dynamics in vivo in the embryonic 
development.  
Functional telomeres are essential for maintaining stemness and genome stability 
in ES and iPS cells and possible markers for evaluating pluripotency. In this way, 
further understanding of telomere reprogramming and maintenance is crucial to 
guarantee the quality of iPS cells and their clinical applications. 
 
TRF1 is essential for the acquisition and maintenance of pluripotency 
TRF1 is a well-established stem cell marker, since it is among the most 
upregulated genes associated with pluripotency (Boue et al., 2010; Ginis et al., 2004; 
Hosseinpour et al., 2013). The fact that we showed that higher levels of TRF1 in iPS 
cells correlated with higher levels of the stem cell marker NANOG and with a higher 
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degree of pluripotency (Schneider et al., 2013), encouraged us to study the role of TRF1 
during reprogramming. On the one hand, Trf1 deletion induces uncapping, fragility and 
a massive DNA damage response at telomeres, resulting in p53 and RB pathways 
activation and ensuing cell cycle arrest. In this way, p53 deletion partially rescues the 
proliferative defects of Trf1 deficiency (Martínez et al. 2009). On the other hand, the 
ectopic expression of the reprogramming factors OCT3/4, KLF4, SOX2 and cMYC 
triggers senescence or apoptosis by upregulating p53, p16
INK4a 
and p21
CIP1
 (Banito et al., 
2009). Hence, these tumor suppressors have been defined as a barrier for 
reprogramming, as they prevent the reprogramming of cells presenting DNA damage in 
order to maintain genome stability. p53 deletion results in an increase in the 
reprogramming efficiency and allows the reprogramming of cells with telomere 
damage, like G3 Terc
-/-
 MEFs (Marion et al., 2009b). Thus, we tried to reprogram Trf1 
knockout MEFs in a p53-null background. However, Trf1-deficient MEFs completely 
failed to reprogram, even in the absence of p53. This is in contrast with what was shown 
before with another shelterin, TPP1. Tpp1 knockout MEFs display telomeric aberrations 
similar to those of Trf1 knockout MEFs, like multitelomeric signals and end-to-end 
fusions. Nevertheless, they are amenable to reprogram, although with lower efficiency 
than wild-type MEFs (Tejera et al., 2010). 
Furthermore, conditional deletion of Trf1 in already established iPS cells lead to 
rapid elimination of iPS colonies coincidental with increased DNA damage and 
apoptosis, demonstrating that protection from telomere damage by TRF1 is essential for 
the maintenance of pluripotency. IPS cells have been described to be highly sensitive to 
DNA damage (Momcilovic et al., 2010). It is known that pluripotent stem cells have 
higher levels of p53 than differentiated cells (Sabapathy et al., 1997), but the majority of 
it is located in the cytoplasm (Solozobova et al., 2009), suggesting that p53 regulation 
may differ between ES and somatic cells. Thus, it would be interesting to study whether 
the apoptosis seen after Trf1 deletion in iPS cells is p53-dependent. Similar experiments 
were done in ES cells with a milder phenotype, as the majority of the conditional Trf1-
deficient ES cells survived in culture. Trf1-deficient ES cells showed growth defects 
and chromosomal instability, with a moderate increase in the levels of apoptosis (Iwano 
et al., 2004). These differences could be due to more sensitivity to genome instability in 
iPS cells compared to ES cells, but also to the fact that they removed the 4-OHT after 
Discussion 
104 
 
two days, while we maintained the treatment. Moreover, it has been published that  
some of the phenotypes in Trf1 knockout mouse ES cells can be partially rescued by the 
overexpression of other components of the shelterin complex (Okamoto et al., 2008). 
Further studies are needed to confirm this in iPS cells and during the reprogramming 
process. 
Together, these results suggest that TRF1 is a key factor for reprogramming of 
differentiated cells into iPS cells as well as for the maintenance of pluripotency.  
 
Trf1 overexpression during reprogramming has no effect in the reprogramming 
efficiency 
 The reprogramming process is a very slow and inefficient process and this is one 
of the main limitations for the clinical applications of iPS cells. In this regard, 
overexpression of factors that could positively affect reprogramming efficiency is a 
good strategy for the amelioration of the reprogramming technique.  
 In line with a role for TRF1 in stemness, it was previously described that TRF1 
upregulation during the process of induction of pluripotency is uncoupled from net 
telomere elongation, as indicated by induction of TRF1 in iPS cells defective for the 
shelterin component TPP1, previously shown by us to fail to elongate telomeres during 
reprogramming (Schneider et al., 2013; Tejera et al., 2010). This notion suggests that 
TRF1 could also have functions independent from telomere maintenance during 
reprogramming. Based on this, we reprogrammed MEFs adding TRF1 to the three 
Yamanaka factors cocktail or with combinations of two of the factors. Strikingly, 
overexpression of Trf1 during reprogramming had no effect in the reprogramming 
efficiency. Similarly, TRF1 was not able to replace any of the Yamanaka factors in the 
reprogramming cocktail. Thus, we conclude that even if TRF1 is essential for 
reprogramming and significantly upregulated during this process, its ectopic expression 
at the beginning of the reprogramming does not improve the efficiency of iPS cell 
generation. 
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Trf1 overexpression has been reported to have several adverse effects. TRF1 
protein has been described as a negative regulator of telomere length, apparently 
regulating telomerase in cis without affecting its expression (Ancelin et al., 2002; 
Smogorzewska et al., 2000; van Steensel and de Lange, 1997). In addition, transgenic 
K5-Trf1 mice which overexpress Trf1 in the epithelial tissues, showing 2 to 4 more 
TRF1 density at telomeres, display shorter telomeres in the epidermis, indicating that 
TRF1 also acts as a negative regulator of telomere length in mice. Besides, K5-Trf1 
cells show increased end-to-end, chromosomal fusions, multitelomeric signals and 
increased telomere recombination, implying an impact of TRF1 overexpression on 
telomere integrity (Muñoz et al. 2009). Furthermore, TRF1 is a mediator of telomere 
associations in mammalian cells and its overexpression in mouse ES cells prevents 
proper telomere resolution during mitosis and results in telomere anaphase bridges.  
As telomeres elongate during the reprogramming process, TRF1 could be 
essential for the correct capping and telomere replication. Nevertheless, it remains 
unclear which is the regulation and function of TRF1 in the absence of telomeric 
elongation during the reprogramming of Tpp1
/
-Cre MEFs. Recently, it has been 
reported in telomerase immortalized human fibroblasts that at the initial phases of 
transformation both TRF1 and TRF2 proteins are in vast excess with respect to telomere 
length, pointing to a role of these proteins in tumorigenesis (Chiodi et al., 2013). It 
would be interesting to study if the density of TRF1 in these iPS cells is higher than in 
wild-type iPS cells and if this could affect the integrity of telomeres in these cells.  
 
Tert and Tpp1 overexpression during reprogramming 
Wnt/ -catenin pathway has a role in maintenance of ESCs both in humans and mice. -
catenin is constitutively phosphorylated by Glycogen synthase kinase-3 (GSK-3), 
inducing its ubiquitylation and degradation.  However, the presence of Wnt3a leads to 
GSK-3 inhibition and activation of -catenin. It has been reported that stimulation of the 
Wnt/ -catenin pathway by the addition of the soluble factor Wnt3a to the medium 
enhances reprogramming (Marson et al., 2008). Besides, addition of GSK-3 inhibitors 
like CHIR has been demonstrated to sustain the pluripotent state of ESCs (Sato N, 
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2004) and to facilitate transition to naive pluripotency in partially reprogrammed (pre-
iPS) cells (Theunissen et al., 2011). -catenin overexpression, especially at the initial 
stages of reprogramming, also increases the efficiency of this process (Zhang et al., 
2014). TERT directly modulates Wnt/-catenin signalling by serving as a cofactor in a 
-catenin transcriptional complex (Park et al., 2009). In this sense, Tert overexpression 
during reprogramming could positively modulate reprogramming efficiency by 
activation of -catenin. As TPP1 is necessary for the recruitment of telomerase and the 
subsequent telomere elongation during the formation of iPS cells (Tejera et al., 2010), 
its overexpression could also influence the process of reprogramming. Strikingly, we 
showed that overexpression of Tert, Tpp1 or the combination of both during 
reprogramming did not have any effect in the reprogramming efficiency.  
C-MYC is a well described trancriptional activator of Tert (Flores et al., 2006) 
Surprisingly, we showed a higher increase in Tert expression in MEFs reprogrammed 
with 3F than with 4F. We have to take into account that MEFs infected with 4F 
reprogram much faster than 3F MEFs. Besides, addition of c-MYC to the 
reprogramming cocktail induces a lot of cell death at the beginning, which could explain 
the differences. On top of that, a recent publication described for the first time dual roles 
of c-MYC in the regulation of human telomerase, as they showed activation of hTERT 
promoter upon c-MYC/MAX downregulation. Thus, they  concluded that c-MYC/Max 
is involved not only in activating hTERT transcription but also in maintaining the 
repressive states of hTERT promoter in somatic cells (Zhao et al., 2014). It would be 
interesting to study if this phenomenon is reproduced in mice. 
As we said before, TERT has extra-telomeric functions, some of them dependent 
on the formation of the TERT/Terc complex. For instance, the telomere length-
independent positive effects shown in growth upon Tert overexpression in MEFs are 
dependent of the formation of the TERT/Terc complex (Geserick et al., 2006). Terc is 
also required for the tumor-promoting effects of Tert overexpression in K5-Tert mice. 
Furthermore, increased expression of Tert in a Terc
-/-
 context has inhibitory effects, 
independently of telomere length or telomerase activity (Cayuela et al., 2005).  Tert 
expression has been described to be the limiting factor for telomere maintenance in 
studies done in ES cells (Liu et al., 2000). In contrast, another group published that it 
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was Terc and not Tert what limits telomere elongation during embryonic and early 
postnatal in vivo development (Chiang et al., 2004). In this sense, it is possible that Terc 
overexpression combined with Tert overexpression during reprogramming had a 
positive effect in reprogramming efficiency. 
As we said before, Tert
-/-
 cells were reprogrammed with lower efficiency than 
wild-type cells even if they had similar telomere length, suggesting that TERT has 
extra-telomeric functions during reprogramming (Kinoshita et al., 2014). Nevertheless, 
these experiments were done in TTFs, which have been described to follow different 
dynamics in the overexpression of telomerase components during reprogramming (Zuo 
et al., 2012). In this paper, they overexpressed Tert in Terc
-/-
 TTFs, but they did not 
report anything about the effect of Tert overexpression in wild-type TTFs. It would be 
interesting to study if Tert overexpression has the same effect on TTFs than in MEFs in 
reprogramming efficiency. 
 In contrast to what we show in MEFs, TERT overexpression in human 
keratinocyte cell lines leads to an increase in reprogramming efficiency (Utikal et al., 
2009). TERT induces immortalization in human cells. Thus, the long-term proliferative 
potential and not higher growth rates is what leads to an enhancement of the 
reprogramming ability in these cells. In mice Tert overexpression alone does not lead to 
immortalization of MEFs. Nevertheless, it facilitates their spontaneous immortalization 
and increases their colony-forming capacity upon activation of oncogenes (Geserick et 
al., 2006). It would be interesting to overexpress Tert in senescent MEFs at higher 
passages.  
The long and stable telomeres of pluripotent cells might be an additional 
mechanism to protect chromosome integrity. Tert overexpression confers greater 
resistance to oxidative stress  in mouse ES cells (Armstrong et al., 2005). Since iPS 
cells are very sensitive to DNA damage compared to somatic cells, Tert overexpression 
could be determinant for the maintenance of genomic stability in IPS cells. Further 
studies in iPS cells obtained from MEFs overexpressing Tert during reprogramming are 
needed to analyze their genomic stability and differentiation potential.  
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Shelterin and telomerase dynamics during reprogramming 
Regarding telomerase components, we showed a marked increased in Terc at the 
end of reprogramming, which is maintained in established iPS cells. Terc promoter is 
regulated by OCT3/4 and NANOG in pluripotent cells (Agarwal et al., 2010). In this 
sense, the increase seen in Terc could be explained by OCT3/4 acting in a second wave 
at the end of reprogramming, as described by Polo and colleagues Overexpression of 
Tert was seen at the beginning of reprogramming, coincidental with c-MYC and KLF4, 
known activators of Tert transcription, acting in the first wave during reprogramming 
(Polo et al., 2012). Nevertheless, Tert levels decreased at the end of reprogramming, 
showing a similar expression in MEFs and iPS cells. There has been controversy in 
relation with Tert expression during reprogramming. While TERT upregulation was 
described to be a late event in the reprogramming process (Stadtfeld et al., 2008a), other 
publications have shown an early activation of this gene (Wang et al., 2012; Zuo et al., 
2012). In this way, both telomere length and telomerase activity have been described to 
show high heterogeneity among the different iPS clones. Besides, telomerase activity is 
not only dependent on Tert and Terc expression, but also on other  factors like 
recruitment to telomeres,  localization in Cajal bodies or interaction with DKC1, which 
is also increased in human iPS cells (Batista et al., 2011; Mah et al., 2011).  
With respect to shelterins, we showed a slight increased in all the shelterins at the 
beginning of reprogramming. As they have essential roles in telomere protection, 
elongation, DDR inhibition and replication, it makes sense that they also increased 
during the process of reprogramming. Nevertheless, most of them come back to initial 
levels in iPS cells. This suggests that shelterins could also suffer post-transcriptional 
regulation in the process of reprogramming. TRF1 and POT1A are the only shelterins 
that appeared to show higher expression in IPS cells. In a paper from 2012, they 
reported a map of OCT3/4, SOX2, KLF4 and c-MYC on the human genome during the 
first 48 hours of fibroblasts reprogramming by ChIP-seq (Soufi et al., 2012). In another 
work done in mouse, they carried out genome-wide analysis of the binding of the four 
transcription factors in ES cells, iPS cells and partially reprogrammed iPS cells 
(Sridharan et al., 2009). In order to set light into the regulation of shelterins and 
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telomerase, we studied the binding of the reprogramming factors to these proteins 
promoters in these data (Table 10-11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
    
Occupancy of O, S, K and M 
     Gene ES cells iPS cells pre-iPS cells 
 
O S K M O S K M O S K M 
Trf1 - - - - - - - - - - - - 
Trf2 - + - + - - - - - - - + 
Tpp1 - - - - - - - - - - - - 
Pot1a - - - + - - - + - - - + 
Rap1 - - - - - - - - - - - - 
Tin2 - - - - - - - - - - - - 
Tert - - - + - - - - - - - - 
Dkc1 - - - + - - - + - - - + 
Gene 
Occupancy of O, S, K and M at 48 hr 
O S K M 
TRF1 + + + - 
TRF2 - + - + 
TPP1 - - - - 
POT1 - - - - 
RAP1 + + + + 
TERT - - - - 
DKC1 - - - - 
Table 10: Chromatin ocuppancy within 20 kb upstream TSS and gene body (peaks 
called with MACS at 0.005 FDR, * peaks within the OCT3/4, SOX2, KLF4 and c-MYC 
coding regions were not considered). +: bound; -= not bound (Adapted from Soufi et al., 
2012). 
Table 11: Average binding data of O, S, K and M to the promoters of shelterins and 
telomerase in ES, iPS and pre-iPS cells += bound; -= not bound. Adapted from (Sridharan et 
al., 2009). 
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Surprisingly, they did not see binding of OCT3/4 to the Trf1 promoter in ES and 
iPS cells (Table 11). This is in controversy with what we previously showed (Schneider 
et al.) 2013), indicating that these data need to be validated. Nevertheless, we showed 
binding of c-MYC to Pot1a promoter in ES, iPS and pre-iPS cells and of SOX2 and c-
MYC to Trf2 promoter in ES cells. Validation of these data by ChIP would give us 
information about the regulation of these shelterins during reprogramming.
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1. The component of the shelterin complex TRF1 show restricted binding to 
telomeres in vivo in MEFs, both in normal conditions and in a context of 
telomere shortening. 
2. TRF1 protein is essential for the process of nuclear reprogramming to iPS cells 
and for the maintenance of already established iPS cells and its downregulation 
decreases dramatically the efficiency of reprogramming. 
3. Even if it is considered as a stem cell marker and highly overexpressed in iPS 
cells, ectopic expression of TRF1 in the cocktail of reprogramming does not 
modulate reprogramming efficiency.  
4. TRF1 is not able to replace any of the three Yamanaka factors during 
reprogramming. 
5. Tert overexpression alone or in combination with Tpp1, the shelterin that 
facilitates its recruitment to telomeres, does not enhance reprogramming 
efficiency in MEFs. 
6. During reprogramming, there is a slight transcriptional upregulation of all the 
components of the shelterin complex, concomitant with an upregulation of the 
components of telomerase, Tert and Terc. 
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1. El componente del complejo shelterina TRF1 se une exclusivamente a telómeros 
in vivo en MEFs, tanto en condiciones normales como en un contexto de 
acortamiento telomérico. 
 
2. La proteína TRF1 es esencial para la adquisición y mantenimiento de la 
pluripotencia y una disminución en su expresión  reduce dramáticamente la 
eficiencia de reprogramación 
 
3. Aunque esté considerado como un marcador de células madre altamente 
sobreexpresado en células iPS, la sobreexpresión de Trf1 en el cocktail de 
reprogramación no aumenta la eficiencia de reprogramación. 
 
4. TRF1 no es capaz de reemplazar a ninguno de los factores de “Yamanaka” 
durante la reprogramación. 
 
5. La sobreexpresión de Tert, sólo o en combinación con Tpp1, la shelterina que 
facilita el reclutamiento de la telomerasa al telómero, no aumenta la eficiencia de 
reprogramación en MEFs. 
 
6. Durante la reprogramación, hay un ligero aumento transcripcional de todos los 
componentes del complejo shelterin, coincidente con un aumento de los 
componentes de la telomerasa, Tert y Terc. 
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